* ArgenX provides update on lead programs in auto-immune
disease and oncology at research and development day in New York
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Thursday, September 22, 2016
BRIEF-Galmed Pharmaceuticals signed agreement with University of California
* Signed an investigator-initiated clinical trial agreement
with University of California, San Diego, school of medicine
Read more
with University of California, San Diego, school of medicine
Read more
BRIEF-Oncology Venture decides on SEK 22.5 mln rights issue
* Board decided to - subject to approval at Extraordinary General Meeting - conduct a rights
issue of up to 774,984 shares at an issue price of 29.00 Swedish crowns per share
Read more
issue of up to 774,984 shares at an issue price of 29.00 Swedish crowns per share
Read more
BRIEF-Allergan and Adamas announce all four dosage strengths of NAMZARIC available throughout U.S.
* Co and Adamas Pharmaceuticals announce all four dosage
strengths of NAMZARIC now available by prescription in
pharmacies throughout U.S.
Source text for Eikon:
Further company coverage:
Read more
strengths of NAMZARIC now available by prescription in
pharmacies throughout U.S.
Source text for Eikon:
Further company coverage:
Read more
UPDATE 1-UK okays Alexion drug costing up to $2 mln but wants price cut
LONDON, Sept 22 (Reuters) - A new drug to treat a rare
inherited bone disorder that was developed by Alexion
Pharmaceuticals and could cost up to 1.5 million pounds
($2 million) a year per patient has been cleared for limited use
by Britain's health cost watchdog.
Read more
inherited bone disorder that was developed by Alexion
Pharmaceuticals and could cost up to 1.5 million pounds
($2 million) a year per patient has been cleared for limited use
by Britain's health cost watchdog.
Read more
BRIEF-Antares Pharma completes QuickShot Testosterone clinical program
* Antares Pharma announces completion of the QuickShot
Testosterone clinical program
Source text for Eikon:
Further company coverage:
Read more
Testosterone clinical program
Source text for Eikon:
Further company coverage:
Read more
BRIEF-OrganiGram's License Capacity Increased by Health Canada
* Health Canada also increased OrganiGram's licensed
production and sales capacity for cannabis oils to 500kg per
annum
Read more
production and sales capacity for cannabis oils to 500kg per
annum
Read more
BRIEF-Egalet announces results after study of ARYMO ER extended-release tablets
* Announces results from a category 3 oral human abuse
potential study and a category 3 intranasal hap study of product
candidate ARYMO ER extended-release tablets
Read more
potential study and a category 3 intranasal hap study of product
candidate ARYMO ER extended-release tablets
Read more
BRIEF-Lumosa Therapeutics completes issuing new shares for T$556.4 mln
* Says it completed issuing 10 million new shares at T$54
per share with amount of T$556.4 million
Read more
per share with amount of T$556.4 million
Read more
BRIEF-Aurobindo Pharma gets USFDA tentative approval for Dolutegravir
* Aurobindo Pharma receives USFDA tentative approval for
Dolutegravir, allowing the product to be launched in the PEPFAR
market
Source text: (http://bit.ly/2cTnfIs)
Further company coverage:
(Bengaluru newsroom)
Read more
Dolutegravir, allowing the product to be launched in the PEPFAR
market
Source text: (http://bit.ly/2cTnfIs)
Further company coverage:
(Bengaluru newsroom)
Read more
Czech Republic - Factors To Watch on Sept 22
PRAGUE, Sept 22 (Reuters) - Here are news stories, press
reports and events to watch which may affect Czech financial
markets on Thursday.
ALL TIMES GMT (Czech Republic: GMT + 2 hours)
=========================ECONOMIC DATA==========================
Real-time economic data releases....................
Summary of economic data and forecasts...........
Recently released economic data..................
Previous stories on Czech data.............
**For
Read more
reports and events to watch which may affect Czech financial
markets on Thursday.
ALL TIMES GMT (Czech Republic: GMT + 2 hours)
=========================ECONOMIC DATA==========================
Real-time economic data releases....................
Summary of economic data and forecasts...........
Recently released economic data..................
Previous stories on Czech data.............
**For
Read more
BRIEF-Kancera: research grant of about EUR 0.5 mln under EU's Horizon 2020
* Receives research grant of about 0.5 million euros ($561,100) within 3 years under frames
of EU's Horizon 2020 program
Read more
of EU's Horizon 2020 program
Read more
Wednesday, September 21, 2016
PRESS DIGEST - Wall Street Journal - Sept 22
Sept 22 (Reuters) - The following are the top stories in the
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
Wall Street Journal. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
PRESS DIGEST- New York Times business news - Sept 22
Sept 22 (Reuters) - The following are the top stories on the
New York Times business pages. Reuters has not verified these
stories and does not vouch for their accuracy.
Read more
New York Times business pages. Reuters has not verified these
stories and does not vouch for their accuracy.
Read more
REFILE-UPDATE 2-Chan Zuckerberg Initiative pledges $3 billion to fight disease
SAN FRANCISCO, Sept 21 (Reuters) - Facebook Chief Executive
Mark Zuckerberg and his wife Priscilla Chan on Wednesday pledged
more than $3 billion toward a plan to "cure, prevent or manage
all disease within our children's lifetime."
Read more
Mark Zuckerberg and his wife Priscilla Chan on Wednesday pledged
more than $3 billion toward a plan to "cure, prevent or manage
all disease within our children's lifetime."
Read more
UPDATE 1-Novo Nordisk to supply insulin at discount to poorest nations
NEW YORK, Sept 21 (Reuters) - Danish drugmaker Novo Nordisk
A/S pledged on Wednesday to provide insulin at
steeply discounted prices in the world's least-developed nations
in what it is calling its "access to insulin commitment."
Read more
A/S pledged on Wednesday to provide insulin at
steeply discounted prices in the world's least-developed nations
in what it is calling its "access to insulin commitment."
Read more
UPDATE 2-U.S. lawmakers blast Mylan CEO over 'sickening' EpiPen price hikes
WASHINGTON, Sept 21 (Reuters) - U.S. lawmakers on Wednesday
blasted Mylan NV Chief Executive Heather Bresch for
sharply increasing prices for the EpiPen emergency allergy
treatment at a congressional hearing in which Republicans and
Democrats questioned the reasons behind rising U.S. drug costs.
Read more
blasted Mylan NV Chief Executive Heather Bresch for
sharply increasing prices for the EpiPen emergency allergy
treatment at a congressional hearing in which Republicans and
Democrats questioned the reasons behind rising U.S. drug costs.
Read more
Obesity, violence hamper U.S. progress on UN health goals - study
LONDON, Sept 21 (Reuters) - The United States performs
poorly in U.N. rankings on progress towards global health goals
due to its high levels of violence, alcohol abuse and childhood
obesity, a study has found.
Read more
poorly in U.N. rankings on progress towards global health goals
due to its high levels of violence, alcohol abuse and childhood
obesity, a study has found.
Read more
BRIEF-Sanford reports a passive stake of 9.7 percent in Caladrius Biosciences
* Sanford reports a passive stake of 9.7 percent in
Caladrius Biosciences Inc as of Sept. 14 - SEC filing
Source text for Eikon:
Further company coverage:
Read more
Caladrius Biosciences Inc as of Sept. 14 - SEC filing
Source text for Eikon:
Further company coverage:
Read more
UnitedHealth trims drug coverage, including Sanofi insulin
Sept 21 (Reuters) - UnitedHealth Group Inc, the
largest U.S. health insurer, will stop covering several
brand-name drugs as of next year, reinforcing a trend of payers
steering prescriptions to lower-priced options.
Read more
largest U.S. health insurer, will stop covering several
brand-name drugs as of next year, reinforcing a trend of payers
steering prescriptions to lower-priced options.
Read more
UPDATE 1-Chan-Zuckerberg Initiative pledges $3 billion to curing, managing disease
SAN FRANCISCO, Sept 21 (Reuters) - Facebook Chief Executive
Mark Zuckerberg and his wife, Priscilla Chan, on Wednesday
pledged more than $3 billion toward a plan to "cure, prevent or
manage all disease within our children's lifetime."
Read more
Mark Zuckerberg and his wife, Priscilla Chan, on Wednesday
pledged more than $3 billion toward a plan to "cure, prevent or
manage all disease within our children's lifetime."
Read more
Chan-Zuckerberg Initiative pledges $3 bln to curing and managing disease
SAN FRANCISCO, Sept 21 (Reuters) - Facebook Chief Executive
Mark Zuckerberg and his wife Priscilla Chan on Wednesday pledged
more than $3 billion toward a plan to "cure, prevent or manage
all disease within our children's lifetime."
Read more
Mark Zuckerberg and his wife Priscilla Chan on Wednesday pledged
more than $3 billion toward a plan to "cure, prevent or manage
all disease within our children's lifetime."
Read more
BRIEF-Anthem and Cigna have accused one another of merger breach - Bloomberg
* Anthem and Cigna have accused one another of merger breach - Bloomberg
Source text - (http://bloom.bg/2cR9knM)
Further company coverage:
(Bengaluru Newsroom)
Read more
Source text - (http://bloom.bg/2cR9knM)
Further company coverage:
(Bengaluru Newsroom)
Read more
BRIEF-Sensorion Initial results of phase 1b clinical study on SENS-111
* Initial Results Of Phase 1b Clinical Study On Sens-111
Presented At The AAO-HNSF Annual Meeting In San Diego
Read more
Presented At The AAO-HNSF Annual Meeting In San Diego
Read more
BRIEF-My Size files for stock shelf of up to 2.23 mln shares
* Files for public offering of up to 2.23 million shares of
co's common stock by the selling stockholders - sec filing
Read more
co's common stock by the selling stockholders - sec filing
Read more
Rift Valley Fever outbreak kills 21 in western Niger
DAKAR, Sept 21 (Thomson Reuters Foundation) - Health workers
in western Niger are racing to contain an outbreak of Rift
Valley fever that has killed at least 21 people over the past
month, an aid agency said on Wednesday.
Read more
in western Niger are racing to contain an outbreak of Rift
Valley fever that has killed at least 21 people over the past
month, an aid agency said on Wednesday.
Read more
Novo Nordisk to supply insulin at discount to poorest nations
NEW YORK, Sept 21 (Reuters) - Danish drugmaker Novo Nordisk
A/S on Wednesday pledged to provide insulin at
steeply discounted prices in the world's least-developed nations
in what it is calling its "access to insulin commitment."
Read more
A/S on Wednesday pledged to provide insulin at
steeply discounted prices in the world's least-developed nations
in what it is calling its "access to insulin commitment."
Read more
BRIEF-BioMarin reviews status of Exon 51 composition of matter
* To seek review of patent trial and appeal board ruling,
for composition of matter claims related to exon 51 skipping
antisense oligonucleotides
Read more
for composition of matter claims related to exon 51 skipping
antisense oligonucleotides
Read more
BRIEF-BiondVax Phase 2b European Trial: Last Patient Out
* Last participant in a European phase 2b clinical trial of
M-001, its universal flu vaccine candidate, has completed final
visit
Read more
M-001, its universal flu vaccine candidate, has completed final
visit
Read more
BRIEF-Sarepta Therapeutics says Edward Kaye appointed CEO, president
* Kaye will continue in his role as Chief Medical Officer
Source text http://bit.ly/2dj97eg
Further company coverage:
Read more
Source text http://bit.ly/2dj97eg
Further company coverage:
Read more
BRIEF-Bluebird Bio's LentiGlobin investigational gene therapy accepted into Europen Medicines Agency's PRIME program
* LentiGlobin(TM) investigational gene therapy for
transfusion-dependent beta-thalassemia accepted into European
Medicines Agency's PRIME program
Source text for Eikon:
Further company coverage:
Read more
transfusion-dependent beta-thalassemia accepted into European
Medicines Agency's PRIME program
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Eleven Biotherapeutics buys Viventia Bio to create oncology company
* Eleven Biotherapeutics acquires Viventia Bio to create
targeted protein therapeutics oncology company
Read more
targeted protein therapeutics oncology company
Read more
BRIEF-Syngene International buys systems biology, pharma services practice of Strand Life Sciences
* Syngene International closes deal with Strand Life
Sciences to purchase systems biology and pharma services
practice
Read more
Sciences to purchase systems biology and pharma services
practice
Read more
BRIEF-Bio Gate H1 net income at around 0.1 mln euros
* In H1 an increase in sales of nearly 30 percent to more
than 2.0 million euros (py: 1.6 million euros)
Read more
than 2.0 million euros (py: 1.6 million euros)
Read more
BRIEF-Xiangxue Pharmaceutical unit to fully acquire food company at 1.8 mln yuan
* Says its subsidiary Guangzhou Asia Beverage Company
Limited will buy 100 percent stake in a Guangzhou-based food
company at 1.8 million yuan
Read more
Limited will buy 100 percent stake in a Guangzhou-based food
company at 1.8 million yuan
Read more
BRIEF-Cancer Genetics says it entered into partnership with Bio Analytical Research Corporation
* Announced today that it has entered into a partnership
with Bio Analytical Research Corporation
Read more
with Bio Analytical Research Corporation
Read more
BRIEF-Xiangxue Pharmaceutical says investment company to invest 2.2 mln yuan in unit
* Says a Guangzhou-based investment company will invest 2.2
million yuan in its subsidiary Guangzhou Asia Beverage Company
Limited
Read more
million yuan in its subsidiary Guangzhou Asia Beverage Company
Limited
Read more
German stocks - Factors to watch on September 21
FRANKFURT, Sept 21 (Reuters) - The DAX top-30 index
looked set to open 0.8 percent higher on Wednesday, according to
premarket data from brokerage Lang & Schwarz at 0620 GMT.
Read more
looked set to open 0.8 percent higher on Wednesday, according to
premarket data from brokerage Lang & Schwarz at 0620 GMT.
Read more
BRIEF-Malin Corp says investee company Novan completes IPO
* A Malin Corporation Plc investee company, Novan Inc today
successfully completed an initial public offering of its shares
Read more
successfully completed an initial public offering of its shares
Read more
Czech Republic - Factors To Watch on Sept 21
PRAGUE, Sept 21 (Reuters) - Here are news stories, press
reports and events to watch which may affect Czech financial
markets on Wednesday.
ALL TIMES GMT (Czech Republic: GMT + 2 hours)
=========================ECONOMIC DATA==========================
Real-time economic data releases....................
Summary of economic data and forecasts...........
Recently released economic data..................
Previous stories on Czech data.............
**For
Read more
reports and events to watch which may affect Czech financial
markets on Wednesday.
ALL TIMES GMT (Czech Republic: GMT + 2 hours)
=========================ECONOMIC DATA==========================
Real-time economic data releases....................
Summary of economic data and forecasts...........
Recently released economic data..................
Previous stories on Czech data.............
**For
Read more
Tuesday, September 20, 2016
BRIEF-Evotec, Bayer to develop new treatments to fight kidney diseases
* Says goal is development of multiple clinical candidates
for treatment of kidney diseases such as chronic kidney disease
in diabetes patients
Read more
for treatment of kidney diseases such as chronic kidney disease
in diabetes patients
Read more
BRIEF-Macrogen receives patent
* Says it receives patent Sept. 21, for fusion protein
comprising C-terminal domain of RET protein and use thereof as a
diagnosing marker
Read more
comprising C-terminal domain of RET protein and use thereof as a
diagnosing marker
Read more
BRIEF-Walvax Biotechnology to sell entire stakes in Shandong Shijie Biological Technology
* Says to sell entire 85 percent stake in Shandong Shijie
Biological Technology Co Ltd for 697 million yuan ($104.46
million)
Read more
Biological Technology Co Ltd for 697 million yuan ($104.46
million)
Read more
BRIEF-Beijing Leadman Biochemistry appoints Zhang Xinyu as finance director
Sept 21 (Reuters) - Beijing Leadman Biochemistry Co Ltd
:
* Says it appoints Zhang Xinyu as finance director
Source text in Chinese: https://goo.gl/sDYjFy
Further company Coverage:
(Beijing Headline News)
Read more
BRIEF-Kolen receives patent
* Says it receives patent on Sept. 21, for voice Coil Motor
Auto focus module and Camera adopting the module
Read more
Auto focus module and Camera adopting the module
Read more
PRESS DIGEST- Financial Times - Sept 21
Sept 21 (Reuters) - The following are the top stories in the
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
BRIEF-Emad Rizk of Accuray tendered his resignation from the board
* On september 16, 2016, Emad Rizk tendered his resignation
from the board of directors - SEC filing
Read more
from the board of directors - SEC filing
Read more
BRIEF-Monsanto Co - Bayer not required to take any material adverse divestiture action
* Bayer not required to take any divestiture action that
would likely result in 1-year loss of net sales to Bayer, co in
excess of $1.6 billion
Read more
would likely result in 1-year loss of net sales to Bayer, co in
excess of $1.6 billion
Read more
BRIEF-Mast reports top-line results from phase 3 study in Sickle Cell Disease
* No statistically significant differences between treatment
groups in intent-to-treat population across 2 secondary efficacy
endpoints
Read more
groups in intent-to-treat population across 2 secondary efficacy
endpoints
Read more
BRIEF-Fortress biotech enters into credit facility agreement with opus point healthcare innovations fund
* On Sept. 14, Co entered into a credit facility agreement
with Opus Point Healthcare Innovations Fund, Lp- SEC filing
Read more
with Opus Point Healthcare Innovations Fund, Lp- SEC filing
Read more
BRIEF-Adamas announces results of Ease Lid 3
* Announces results of Ease Lid 3, a pivotal trial of ADS
5102 for the treatment of Levodopa-induced Dyskinesia (lid) in
parkinson's disease patients at the 4th world parkinson congress
Read more
5102 for the treatment of Levodopa-induced Dyskinesia (lid) in
parkinson's disease patients at the 4th world parkinson congress
Read more
U.S. Senate finance committee asks for Mylan EpiPen rebate investigation
NEW YORK, Sept 20 (Reuters) - The U.S. Senate Finance
Committee on Tuesday said it had asked the U.S. Department of
Health and Human Services to investigate the rebates to state
Medicaid programs for Mylan Inc's EpiPen treatment.
Read more
Committee on Tuesday said it had asked the U.S. Department of
Health and Human Services to investigate the rebates to state
Medicaid programs for Mylan Inc's EpiPen treatment.
Read more
BRIEF-PHM proposes separation into two new industry-leading public companies
* Co announced that its Board of directors has approved
plans to separate into two companies
Source text for Eikon:
Further company coverage:
Read more
plans to separate into two companies
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Enzo Biochem announces New York State Health Department approval of new cardiac assay
* Enzo Biochem announces New York State Health Department
approval of new easily adaptable, cost effective cardiac assay
Read more
approval of new easily adaptable, cost effective cardiac assay
Read more
UPDATE 1-West Virginia investigating Mylan over EpiPen pricing
NEW YORK, Sept 20 (Reuters) - The state of West Virginia is
investigating whether Mylan NV violated antitrust law or
defrauded the state's Medicaid program in connection with its
EpiPen device.
Read more
investigating whether Mylan NV violated antitrust law or
defrauded the state's Medicaid program in connection with its
EpiPen device.
Read more
EU mergers and takeovers (Sept 20)
BRUSSELS, Sept 20 (Reuters) - The following are mergers
under review by the European Commission and a brief guide to the
EU merger process:
Read more
under review by the European Commission and a brief guide to the
EU merger process:
Read more
West Virginia investigating Mylan over EpiPen pricing
Sept 20 (Reuters) - The state of West Virginia is
investigating whether Mylan NV violated antitrust laws
or defrauded the state's Medicaid program in connection with its
EpiPen device.
Read more
investigating whether Mylan NV violated antitrust laws
or defrauded the state's Medicaid program in connection with its
EpiPen device.
Read more
NEWSMAKER-Breaking the mould: GSK picks Big Pharma's first female CEO
LONDON, Sept 20 (Reuters) - Emma Walmsley, GlaxoSmithKline's
incoming CEO, breaks the mould as the first woman to
lead a top global drugmaker and stands out among Big Pharma
bosses as a consumer brands guru rather than a prescription
medicines expert.
Read more
incoming CEO, breaks the mould as the first woman to
lead a top global drugmaker and stands out among Big Pharma
bosses as a consumer brands guru rather than a prescription
medicines expert.
Read more
South Africa's Tutu responding well to treatment -family
CAPE TOWN, Sept 20 (Reuters) - South African anti-apartheid
activist and veteran cleric, Archbishop Desmond Tutu, was
responding well to a new course of antibiotics, his daughter
said on Tuesday, following social media reports her father had
died.
Read more
activist and veteran cleric, Archbishop Desmond Tutu, was
responding well to a new course of antibiotics, his daughter
said on Tuesday, following social media reports her father had
died.
Read more
GRAPHIC-Credit Suisse sees scope for UK mining dividend rise
LONDON, Sept 20 (Reuters) - Dividend yields at British
mining companies have hit a five-year low just as cash flows in
the sector improve, prompting some analysts to call for higher
payouts as early as next year.
Read more
mining companies have hit a five-year low just as cash flows in
the sector improve, prompting some analysts to call for higher
payouts as early as next year.
Read more
BRIEF-Can-Fite reports new data on CF102'S liver protective & regenerative properties published in scientific journal
* CF102 is currently in global phase II trial for liver
cancer and preparing for phase II trial in Nash
Read more
cancer and preparing for phase II trial in Nash
Read more
BRIEF-Lannett announces approval for Buprenorphine and Naloxone Sublingual Tablets
* Received approval from FDA of ANDA for Buprenorphine and
Naloxone Sublingual Tablets, 2 mg/0.5 mg and 8 mg/2 mg
Read more
Naloxone Sublingual Tablets, 2 mg/0.5 mg and 8 mg/2 mg
Read more
BRIEF-Bellerophon therapeutics announces management transition
Sept 20 (Reuters) - Bellerophon Therapeutics Announces
Planned Management Transition by year end
Read more
Planned Management Transition by year end
Read more
Drugmakers pledge to clean up antibiotic factories, curb overuse
Sept 20 (Reuters) - Thirteen leading drugmakers promised on
Tuesday to clean up pollution from factories making antibiotics
and take steps to curb overuse of the medicines as part of a
drive to fight the rise of drug-resistant superbugs.
Read more
Tuesday to clean up pollution from factories making antibiotics
and take steps to curb overuse of the medicines as part of a
drive to fight the rise of drug-resistant superbugs.
Read more
BRIEF-Lansen Pharmaceutical says unit entered into framework agreement with Natural Dailyheath
* Maximum value of transactions between parties contemplated
during term will be rmb80 million
Read more
during term will be rmb80 million
Read more
CORRECTED-UPDATE 2-GlaxoSmithKline names insider Emma Walmsley as new CEO
LONDON, Sept 20 (Reuters) - GlaxoSmithKline said on
Tuesday it had chosen its head of consumer healthcare, Emma
Walmsley, as its new chief executive, after considering internal
and external candidates.
Read more
Tuesday it had chosen its head of consumer healthcare, Emma
Walmsley, as its new chief executive, after considering internal
and external candidates.
Read more
BRIEF-Chengdu Huasun's unit signs auto parts industrial park project worth 126.6 mln yuan
* Says unit signs auto parts industrial park project worth
126.6 million yuan ($18.98 million)
Read more
126.6 million yuan ($18.98 million)
Read more
Monday, September 19, 2016
GlaxoSmithKline names consumer head Walmsley new CEO
LONDON, Sept 20 (Reuters) - GlaxoSmithKline said on
Tuesday it had chosen Emma Walmsley, head of consumer
healthcare, as its new chief executive, after considering
internal and external candidates.
Read more
Tuesday it had chosen Emma Walmsley, head of consumer
healthcare, as its new chief executive, after considering
internal and external candidates.
Read more
BRIEF-Formycon H1 turnover down at 8.76 mln euros
* H1 turnover was 8.76 million euros ($9.79 million),
compared to 9.82 million euros in same period previous year
Read more
compared to 9.82 million euros in same period previous year
Read more
UK Stocks-Factors to watch on Sept. 20
Sept 20 (Reuters) - Britain's FTSE 100 index is seen opening 1 to 7
points lower, or down as much as 0.1 percent on Tuesday, according to financial
bookmakers.
* The UK blue chip index closed at 6,813.55 on Monday, up 103.27 points or
1.5 percent, thanks to a rise in commodity-related stocks.
* UNILEVER: Unilever said on Monday it would buy Seventh
Generation, a U.S.-based maker of "green" home and personal care goods, its
latest deal aimed at boosting the faster-growing part of it
Read more
points lower, or down as much as 0.1 percent on Tuesday, according to financial
bookmakers.
* The UK blue chip index closed at 6,813.55 on Monday, up 103.27 points or
1.5 percent, thanks to a rise in commodity-related stocks.
* UNILEVER: Unilever said on Monday it would buy Seventh
Generation, a U.S.-based maker of "green" home and personal care goods, its
latest deal aimed at boosting the faster-growing part of it
Read more
BRIEF-Onco Therapy Science to start Phase I clinical study for breast cancer patients in U.S.
* Says the co will conduct Phase I clinical study of OTS167,
a MELK specific inhibitor, for breast cancer patients following
the acceptance of the protocol by the U.S. Food and Drug
Administration
Read more
a MELK specific inhibitor, for breast cancer patients following
the acceptance of the protocol by the U.S. Food and Drug
Administration
Read more
Three private equity firms bid for GE's Hyundai Card stake - Invest Chosun
SEOUL, Sept 20 (Reuters) - Three private equity firms are
bidding for General Electric's 43 percent stake in its
South Korean credit card joint venture, Hyundai Card, in a deal
that may be worth more than 600 billion won ($537 million),
Invest Chosun reported on Tuesday.
Read more
bidding for General Electric's 43 percent stake in its
South Korean credit card joint venture, Hyundai Card, in a deal
that may be worth more than 600 billion won ($537 million),
Invest Chosun reported on Tuesday.
Read more
BRIEF-Shire priced its public offering of $12.1 bln aggregate principal amount of senior notes
* Priced its inaugural public offering of $12.1 billion
aggregate principal amount of senior notes
Read more
aggregate principal amount of senior notes
Read more
BRIEF-Cirrus Logic set to join S&P Midcap;400 Amphastar to join S&P Smallcap 600
* Cirrus Logic set to join S&P Midcap 400; Amphastar
Pharmaceuticals to join S&P Smallcap 600
Source text for Eikon:
Read more
Pharmaceuticals to join S&P Smallcap 600
Source text for Eikon:
Read more
PRESS DIGEST- Financial Times - Sept 20
Sept 20 (Reuters) - The following are the top stories in the
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
BRIEF-FDA approves 6-month primary end point for the Lutonix
* Approves 6 Primary efficacy end point in clinical trial is
a composite of limb salvage and primary patency at 6 months
Read more
a composite of limb salvage and primary patency at 6 months
Read more
BRIEF-Moody's says expectations for Abbott's ratings unchanged
* Moody's says expectations for Abbott's ratings unchanged
following news of medical optics sale
Source text for Eikon:
Further company coverage:
Read more
following news of medical optics sale
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Response Biomedical receives court approval of going-private transaction
* Response Biomedical Corp receives court approval of
going-private transaction
Source text for Eikon:
Further company coverage:
Read more
going-private transaction
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Kewaunee Scientific awarded $18.5 million contract in Kuwait
* Kewaunee Scientific awarded $18.5 million contract in
Kuwait
Source text for Eikon:
Further company coverage:
Read more
Kuwait
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Xencor inc files for mixed shelf of upto $300 million
* Files for mixed shelf of upto $300 million - SEC filing
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Arvida Group to acquire three villages for NZ$66 mln
* Acquisition immediately accretive to underlying earnings
with 6% lift in proforma FY17 EPS
Read more
with 6% lift in proforma FY17 EPS
Read more
BRIEF-Remeditex Ventures LLC reports 6.6 pct passive stake in Venaxis
* Remeditex Ventures LLC reports 6.6 pct passive stake in
Venaxis as of September 12, 2016 - SEC Filing
Source - http://bit.ly/2cNHvcY
Further company coverage:
Read more
Venaxis as of September 12, 2016 - SEC Filing
Source - http://bit.ly/2cNHvcY
Further company coverage:
Read more
BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately
* Sarepta therapeutics announces fda accelerated approval of
exondys 51(tm) (eteplirsen) injection, an exon skipping therapy
to treat duchenne muscular dystrophy (dmd) patients amenable to
skipping exon 51
Read more
exondys 51(tm) (eteplirsen) injection, an exon skipping therapy
to treat duchenne muscular dystrophy (dmd) patients amenable to
skipping exon 51
Read more
MOVES-Houlihan Lokey hires Taylor for healthcare group
NEW YORK, Sept 19 (IFR) - Boutique investment bank Houlihan
Lokey said it has hired Marshall Taylor as a managing director
and national healthcare leader in its transaction advisory
services group in Dallas.
Read more
Lokey said it has hired Marshall Taylor as a managing director
and national healthcare leader in its transaction advisory
services group in Dallas.
Read more
BRIEF-Bpifrance grants Nanobiotix a 2 million euros interest-free loan to support final development stage of lead product, NBTXR3
* Bpifrance grants Nanobiotix a 2 million euros ($2.24
million) interest-free loan to support final development stage
of lead product, NBTXR3
Source text for Eikon:
Further company coverage:
($1 = 0.8948 euros)
(Gdynia Newsroom)
Read more
million) interest-free loan to support final development stage
of lead product, NBTXR3
Source text for Eikon:
Further company coverage:
($1 = 0.8948 euros)
(Gdynia Newsroom)
Read more
BRIEF-Invent Medic now sees to reach target of break-even in H1 2018
* Says multicenter study regarding Tension Free Vaginal Support (TVS) to
start in Q4 2016, which is one quarter later than planned
Read more
start in Q4 2016, which is one quarter later than planned
Read more
BRIEF-Mabvax Therapeutics provides interim progress on programs
* Mabvax therapeutics reports on interim progress on its
programs including the phase i clinical trial for therapeutic
antibody treatment of pancreatic cancer
Read more
programs including the phase i clinical trial for therapeutic
antibody treatment of pancreatic cancer
Read more
BRIEF-Press Ganey Holdings announces end of go-shop period
* During go-shop period, cos representatives engaged in
solicitation of 26 potential strategic bidders and 50 potential
financial bidders
Read more
solicitation of 26 potential strategic bidders and 50 potential
financial bidders
Read more
BRIEF-Cyxone: Patent approval in US
* Has received patent approved in US
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Florida governor says no Zika transmission in Miami's Wynwood in 45 days
Sept 19 (Reuters) - Florida Governor Rick Scott on Monday
said there has been no local transmission of Zika in 45 days in
the Miami neighborhood of Wynwood, the first site of a
non-travel related case of the virus in the continental United
States.
Read more
said there has been no local transmission of Zika in 45 days in
the Miami neighborhood of Wynwood, the first site of a
non-travel related case of the virus in the continental United
States.
Read more
BRIEF-Biotec Pharmacon confirms reimbursement in another region in Germany
* Receives confirmation of Woulgan being reimbursed by Statutory Health Insurance fund
(krankenkasse) in another region in Germeny
Read more
(krankenkasse) in another region in Germeny
Read more
BRIEF-NuVasive receives FDA 510(k)clearance
* Receives FDA 510(k) clearance reinforcing comprehensive
portfolio supporting pediatric, adolescent and adult spinal
deformity patients
Source text for Eikon:
Further company coverage:
Read more
portfolio supporting pediatric, adolescent and adult spinal
deformity patients
Source text for Eikon:
Further company coverage:
Read more
BRIEF-PlexBio signs license agreement with Denka Seiken for $1 mln
* Says it signed a license agreement with Denka Seiken Co
Ltd to authorize its multiple detection technology platform and
product joint development agreement to Denka Seiken for $1
million
Read more
Ltd to authorize its multiple detection technology platform and
product joint development agreement to Denka Seiken for $1
million
Read more
BRIEF-Active Biotech updates on laquinimod development
* Active Biotech update on laquinimod development: U.S, Food
and Drug Administration rescinds special protocol assessment for
laquinimod
Source text for Eikon:
Further company coverage:
Read more
and Drug Administration rescinds special protocol assessment for
laquinimod
Source text for Eikon:
Further company coverage:
Read more
UPDATE 2-Eastern Aleppo aid stuck in Turkey as Syria truce ends
BEIRUT, Sept 19 (Reuters) - Two 20-truck aid convoys
destined for eastern Aleppo with enough supplies to feed 185,000
people for a month are still stuck in Turkey, a U.N. spokesman
said on Monday, hours after a ceasefire in Syria expired.
Read more
destined for eastern Aleppo with enough supplies to feed 185,000
people for a month are still stuck in Turkey, a U.N. spokesman
said on Monday, hours after a ceasefire in Syria expired.
Read more
Study shines a light on low winter-time male libido
LONDON, Sept 19 (Reuters) - Exposure to bright light can
raise testosterone levels and lead to greater sexual
satisfaction in men with low sexual desire, according to the
results of a small scientific trial.
Read more
raise testosterone levels and lead to greater sexual
satisfaction in men with low sexual desire, according to the
results of a small scientific trial.
Read more
BRIEF-Tonghua Dongbao Pharmaceutical to transfer ginseng tissue culture adventitious technological achievement to Dongbao Industry Group at 12.2 mln yuan
* Says it will transfer its ginseng tissue culture
adventitious technological achievement to Dongbao Industry Group
at 12.2 million yuan
Read more
adventitious technological achievement to Dongbao Industry Group
at 12.2 million yuan
Read more
UPDATE 2-UK Stocks-Factors to watch on Sept 19
Sept 19 (Reuters) - Britain's FTSE 100 index is seen opening up 68
points, or 1 percent, on Monday, according to financial bookmakers, with futures
up 0.94 percent ahead of the cash market open.
Read more
points, or 1 percent, on Monday, according to financial bookmakers, with futures
up 0.94 percent ahead of the cash market open.
Read more
Sunday, September 18, 2016
French and Benelux stocks-Factors to watch on Sept.19
PARIS, Sept 19 (Reuters) - Below are company-related news
and stories from French and Benelux media which could have an
impact on the region's markets or individual stocks.
Read more
and stories from French and Benelux media which could have an
impact on the region's markets or individual stocks.
Read more
Novartis says Entresto linked to higher quality of life scores
ZURICH, Sept 19 (Reuters) - Swiss drugmaker Novartis
said on Monday that a new analysis showed its Entresto
drug was linked to higher quality of life scores among patients
who had been hospitalized with reduced ejection fraction heart
failure.
Read more
said on Monday that a new analysis showed its Entresto
drug was linked to higher quality of life scores among patients
who had been hospitalized with reduced ejection fraction heart
failure.
Read more
Swiss stocks - Factors to watch on Sept 19
ZURICH, Sept 19 (Reuters) - The following are some of the
main factors expected to affect Swiss stocks on Monday:
Read more
main factors expected to affect Swiss stocks on Monday:
Read more
IFR Capital Markets Week Ahead - September 19, 2016
LONDON, Sept 19 (IFR) - Welcome to the IFR Capital Markets
Week Ahead - a new weekly email newsletter from Thomson Reuters
IFR.
TAKING A HIKE
Corporate bond markets are expected to take a breather, with
most issuers set to sit out the next few days ahead of two big
central bank decisions on Wednesday. The US Federal Reserve
could shock markets with its second hike in a decade, while the
Bank of Japan is considering big changes to its mammoth
quantitative easing programme.
Read more
Week Ahead - a new weekly email newsletter from Thomson Reuters
IFR.
TAKING A HIKE
Corporate bond markets are expected to take a breather, with
most issuers set to sit out the next few days ahead of two big
central bank decisions on Wednesday. The US Federal Reserve
could shock markets with its second hike in a decade, while the
Bank of Japan is considering big changes to its mammoth
quantitative easing programme.
Read more
BRIEF-Zhejiang NHU's unit plans JV with Zhejiang Runtu
* Says co's special material unit plans to set up a joint
venture with Zhejiang Runtu Co Ltd
Read more
venture with Zhejiang Runtu Co Ltd
Read more
GE brings off-the-shelf biotech drug factories to Ireland
LONDON, Sept 19 (Reuters) - General Electric is
digging deeper into biotechnology with plans to build four
prefabricated drug factories in Ireland, bringing to Europe a
low-cost manufacturing concept it first pioneered in China.
Read more
digging deeper into biotechnology with plans to build four
prefabricated drug factories in Ireland, bringing to Europe a
low-cost manufacturing concept it first pioneered in China.
Read more
UPDATE 1-Novartis says MS drug cut risk of disability advance in study
ZURICH, Sept 17 (Reuters) - Novartis's
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the Swiss company said on
Saturday, citing a new analysis of a late-stage trial.
Read more
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the Swiss company said on
Saturday, citing a new analysis of a late-stage trial.
Read more
Saturday, September 17, 2016
Novartis says MS drug cut risk of disability advance in study
ZURICH, Sept 17 (Reuters) - Novartis's
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the Swiss company said on
Saturday, citing a new analysis of a late-stage trial.
Read more
investigational multiple sclerosis drug cut the risk of
disability progression in patients with a tough-to-treat form of
the disease versus a placebo, the Swiss company said on
Saturday, citing a new analysis of a late-stage trial.
Read more
UPDATE 2-17-year-old is first minor to be granted euthanasia in Belgium
BRUSSELS, Sept 17 (Reuters) - A 17-year-old has committed
doctor-assisted suicide in Belgium, the first minor to do so
under rules adopted in 2014 allowing euthanasia for people of
all ages, the head of the national committee for euthanasia said
on Saturday.
Read more
doctor-assisted suicide in Belgium, the first minor to do so
under rules adopted in 2014 allowing euthanasia for people of
all ages, the head of the national committee for euthanasia said
on Saturday.
Read more
Belgium reports first case of euthanasia for a minor
BRUSSELS, Sept 17 (Reuters) - A minor has been euthanised in
Belgium in what is the first application of rules adopted by the
country in 2014 allowing doctor-assisted death for children of
all ages, the head of the national committee for euthanasia said
on Saturday.
Read more
Belgium in what is the first application of rules adopted by the
country in 2014 allowing doctor-assisted death for children of
all ages, the head of the national committee for euthanasia said
on Saturday.
Read more
South Africa's Tutu back in hospital after surgery
CAPE TOWN, Sept 17 (Reuters) - South African cleric and
anti-apartheid icon Desmond Tutu was readmitted to hospital on
Saturday to treat an infection following a surgery last week,
his family said.
Read more
anti-apartheid icon Desmond Tutu was readmitted to hospital on
Saturday to treat an infection following a surgery last week,
his family said.
Read more
Friday, September 16, 2016
BRIEF-Pfizer reports positive top-line results from reflections B537-02 study for PF-06438179
* Results confirm similar efficacy of PF-06438179
(Infliximab-pfizer) to Remicade(REG) (Infliximab), in
combination with Methotrexate
Read more
(Infliximab-pfizer) to Remicade(REG) (Infliximab), in
combination with Methotrexate
Read more
UPDATE 1-Perrigo explores sale of royalties of drug Tysabri -sources
Sept 16 (Reuters) - Perrigo Company Plc, the
manufacturer of generic drugs and over the counter medicines
targeted by activist investor Starboard Value LP, is exploring a
sale of the royalties from its multiple sclerosis drug Tysabri,
people familiar with the matter said.
Read more
manufacturer of generic drugs and over the counter medicines
targeted by activist investor Starboard Value LP, is exploring a
sale of the royalties from its multiple sclerosis drug Tysabri,
people familiar with the matter said.
Read more
BRIEF-Tenet enters into an amendment No. 1 to its existing letter of credit facility agreement
* Says on September 15, entered into an amendment no. 1 to
its existing letter of credit facility agreement
Read more
its existing letter of credit facility agreement
Read more
UPDATE 2-Abbott to sell its eye care business to J&J for about $4.33 bln
Sept 16 (Reuters) - Abbott Laboratories said it
would sell its eye care business to Johnson & Johnson
for about $4.33 billion in cash to focus on cardiovascular
devices and diagnostics business.
Read more
would sell its eye care business to Johnson & Johnson
for about $4.33 billion in cash to focus on cardiovascular
devices and diagnostics business.
Read more
BRIEF-Sequenom announces tender offers, consent solicitations for 5 pct convertible senior notes
* Labcorp subsidiary Sequenom Inc. announces tender offers
and consent solicitations for 5 percent convertible senior notes
due 2017 and 5 percent convertible senior exchange notes due
2018
Read more
and consent solicitations for 5 percent convertible senior notes
due 2017 and 5 percent convertible senior exchange notes due
2018
Read more
UPDATE 2-Obama enlists Republican Kasich to push for TPP trade deal
WASHINGTON, Sept 16 (Reuters) - Ohio's Republican Governor
John Kasich took over the White House briefing lectern on Friday
to praise the 12-nation Trans-Pacific Partnership, an unusual
move that shows how hard President Barack Obama wants to push
for the trade deal's approval.
Read more
John Kasich took over the White House briefing lectern on Friday
to praise the 12-nation Trans-Pacific Partnership, an unusual
move that shows how hard President Barack Obama wants to push
for the trade deal's approval.
Read more
California governor signs epinephrine bill, blasts Mylan
SAN FRANCISCO, Sept 16 (Reuters) - California Governor Jerry
Brown on Friday signed a bill to allow businesses across the
state to carry epinephrine auto-injectors, but sharply
admonished drugmaker Mylan NL over its recent price
increases.
Read more
Brown on Friday signed a bill to allow businesses across the
state to carry epinephrine auto-injectors, but sharply
admonished drugmaker Mylan NL over its recent price
increases.
Read more
Novartis says experimental drug helps chronic migraine sufferers
ZURICH, Sept 16 (Reuters) - About 40 percent of chronic
migraine sufferers taking an experimental drug developed by
Novartis and Amgen saw the number of days they
suffered a migraine cut by at least half, beating the placebo in
the trial.
Read more
migraine sufferers taking an experimental drug developed by
Novartis and Amgen saw the number of days they
suffered a migraine cut by at least half, beating the placebo in
the trial.
Read more
Protection of Amazon's biodiversity could fuel "fourth industrial revolution" - study
RIO DE JANEIRO, Sept 16 (Thomson Reuters Foundation) - The
Amazon rainforest holds the biological keys to kick-start a
"fourth industrial revolution" if its biodiversity is protected,
said a study published on Friday.
Read more
Amazon rainforest holds the biological keys to kick-start a
"fourth industrial revolution" if its biodiversity is protected,
said a study published on Friday.
Read more
REFILE- Spiked M&A deals set for record as regulators increase scrutiny
NEW YORK, Sept 16 (IFR) - Bayer will be hoping that its
US$66bn purchase of Monsanto won't succumb to the same failure
that has tripped up many other mergers and acquisitions this
year, as regulators across the globe increase the scrutiny of
deals.
Read more
US$66bn purchase of Monsanto won't succumb to the same failure
that has tripped up many other mergers and acquisitions this
year, as regulators across the globe increase the scrutiny of
deals.
Read more
BRIEF-The Capital Group Compaines increases stake in Capio to 5 pct
* The capital group compaines increases stake in Capio to
7,058,822 shares, corresponding to 5 percent of shares.
Further company coverage:
(Reporting By Johan Ahlander)
Read more
7,058,822 shares, corresponding to 5 percent of shares.
Further company coverage:
(Reporting By Johan Ahlander)
Read more
BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial
* Celgene Corp -Oral Ozanimod efficacy and safety results at
2 years from Phase 2 RADIANCE trial of patients with relapsing
multiple Sclerosis presented at 32nd Ectrims
Read more
2 years from Phase 2 RADIANCE trial of patients with relapsing
multiple Sclerosis presented at 32nd Ectrims
Read more
BRIEF-Aphria says board approves fully funded $24.5 mln capital project
* "Board of Directors approved a fully funded $24.5 million
capital project as first phase of its part III expansion"
Source text for Eikon:
Further company coverage:
Read more
capital project as first phase of its part III expansion"
Source text for Eikon:
Further company coverage:
Read more
Astrazeneca says Forxiga combination beats use of drug alone
FRANKFURT, Sept 16 (Reuters) - AstraZeneca said
combining its Forxiga type-2 diabetes drug with older medicine
Bydureon was more effective at controlling blood sugar levels
than treatment with either drug on its own.
Read more
combining its Forxiga type-2 diabetes drug with older medicine
Bydureon was more effective at controlling blood sugar levels
than treatment with either drug on its own.
Read more
BRIEF-Aphria says board approved a fully funded $24.5 mln capital project as first stage of its Part III expansion
* Aphria Inc says board of directors approved a fully
funded $24.5 million capital project as first phase of its Part
III expansion
Read more
funded $24.5 million capital project as first phase of its Part
III expansion
Read more
BRIEF-Cesca therapeutics to report fiscal Q4 and FY2016 financial results
* Cesca therapeutics to report fiscal fourth quarter and
full year 2016 financial results and provide business update
Source text for Eikon:
Further company coverage:
Read more
full year 2016 financial results and provide business update
Source text for Eikon:
Further company coverage:
Read more
GSK closes UK factory due to flooding
LONDON, Sept 16 (Reuters) - Britain's biggest drugmaker
GlaxoSmithKline said it had been forced to shut a
factory at Maidenhead west of London due to flooding,
potentially causing disruption to the site which produces
toothpaste and mouthwash.
Read more
GlaxoSmithKline said it had been forced to shut a
factory at Maidenhead west of London due to flooding,
potentially causing disruption to the site which produces
toothpaste and mouthwash.
Read more
BRIEF-LifeAssays signs LoI with new distributor in Italy
* Signs letter of intent with new distributor in Italy, EosBio s.r.l.
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Pharmstandard unit increases stake in OTCPharm
* Said on Thursday that Pharmstandard unit
Pharmstandard-Leksredstva increased its stake in company to
10.9233 pct from 7.8736 pct
Read more
Pharmstandard-Leksredstva increased its stake in company to
10.9233 pct from 7.8736 pct
Read more
BRIEF-Ireneusz Plaza sells his entire 16.2 pct stake in Telemedycyna Polska
* Ireneusz Plaza sells 940,000 shares of the company at 0.95
zloty per share lowering his stake in Telemedycyna Polska to 0
percent from 16.2 percent
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
zloty per share lowering his stake in Telemedycyna Polska to 0
percent from 16.2 percent
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Novo Nordisk says semaglutide reduces cardiovascular events by 26 pct
* Says semaglutide-treated diabetes patients had significant
26 pct lower risk of "the primary composite outcome of death"
from cardiovascular causes
Read more
26 pct lower risk of "the primary composite outcome of death"
from cardiovascular causes
Read more
Thursday, September 15, 2016
BRIEF-Stentys H1 operating loss narrows to 4.0 million euros
* Reported on Thursday an H1 operating loss of 4.0 million
euros ($4.49 million) versus a loss of 5.4 million euros a year
ago
Read more
euros ($4.49 million) versus a loss of 5.4 million euros a year
ago
Read more
BRIEF-Hainan Haiyao to set up investment unit
* Says it to invest 100 million yuan to set up a wholly
owned investment subsidiary in Hainan
Read more
owned investment subsidiary in Hainan
Read more
BRIEF-Walvax Biotechnology unit gets patent license
* Says it received a patent license for extraction of
residual DNA with magnetic beads method
Read more
residual DNA with magnetic beads method
Read more
BRIEF-Guizhou Yibai Pharmaceutical's unit plans medical JV, with partners
* Says its unit plans to invest 5.1 million yuan to set up a
minimally invasive surgical joint venture (medical JV), with
eight individuals
Read more
minimally invasive surgical joint venture (medical JV), with
eight individuals
Read more
BRIEF-Oragenics, Koski Family Limited partnership enters into amendment to June 30, 2016 unsecured promissory note
* Co and Koski Family Limited partnership entered into an
amendment to June 30, 2016 unsecured promissory note - SEC
filing
Read more
amendment to June 30, 2016 unsecured promissory note - SEC
filing
Read more
BRIEF-Agilent Technologies prices $300 mln of senior notes
* Notes will mature in September 2026 and will bear interest
at an annual rate of 3.050 percent
Source text for Eikon:
Further company coverage:
Read more
at an annual rate of 3.050 percent
Source text for Eikon:
Further company coverage:
Read more
UPDATE 2-Samsung to replace or refund 1 mln U.S. Galaxy Note 7 phones
Sept 15 (Reuters) - Samsung Electronics Co Ltd
formally recalled 1 million Galaxy Note 7 smartphones sold in
the United States, replacing or refunding the flagship phones,
whose susceptibility to catching fire has damaged the image of
the Korean powerhouse.
Read more
formally recalled 1 million Galaxy Note 7 smartphones sold in
the United States, replacing or refunding the flagship phones,
whose susceptibility to catching fire has damaged the image of
the Korean powerhouse.
Read more
Study confirms Zika causes brain birth defects, questions remain
LONDON, Sept 15 (Reuters) - Early results from a crucial
case-control study in Brazil have confirmed a direct causal link
between Zika virus infection in pregnant women and the brain
damaging birth defect microcephaly in their babies, scientists
said on Thursday.
Read more
case-control study in Brazil have confirmed a direct causal link
between Zika virus infection in pregnant women and the brain
damaging birth defect microcephaly in their babies, scientists
said on Thursday.
Read more
BRIEF-Lattice closes first tranche of private placement
* Lattice Biologics closes first tranche of private
placement announced on september 13, 2016
Source text for Eikon:
Further company coverage:
Read more
placement announced on september 13, 2016
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Teleflex approves an increase in size of board from nine to ten directors
* Teleflex Inc says approved an increase in size of board
from nine to ten directors and elected Gretchen R. Haggerty to
board to fill vacancy
Source text - http://bit.ly/2cMMtZt
Further company coverage:
Read more
from nine to ten directors and elected Gretchen R. Haggerty to
board to fill vacancy
Source text - http://bit.ly/2cMMtZt
Further company coverage:
Read more
BRIEF-Amgen presents positive data at EHMTIC 2016, Erenumab reduces migraine
* Amgen presents positive data at EHMTIC 2016 demonstrating
erenumab significantly reduces monthly migraine days in patients
with chronic migraine
Read more
erenumab significantly reduces monthly migraine days in patients
with chronic migraine
Read more
BRIEF-Viveve reports resignation of Brigitte Smith from company board of directors
* Viveve(R) announces resignation of Brigitte Smith from
company board of directors
Source text for Eikon:
Further company coverage:
Read more
company board of directors
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Agilent Technologies announces offering of senior notes
* Intends to use proceeds from offering to repay all amounts
outstanding under its revolving credit facility
Source text for Eikon:
Further company coverage:
Read more
outstanding under its revolving credit facility
Source text for Eikon:
Further company coverage:
Read more
UPDATE 2-Teva, Intel to develop wearable tech for Huntington's disease
Sept 15 (Reuters) - Teva Pharmaceutical Industries Ltd
said on Thursday it was collaborating with Intel Corp
to develop a wearable technology platform to track the
progression of disease in patients with Huntington's, a fatal
degenerative disorder.
Read more
said on Thursday it was collaborating with Intel Corp
to develop a wearable technology platform to track the
progression of disease in patients with Huntington's, a fatal
degenerative disorder.
Read more
Fitch: Bayer, Monsanto Deal Structure Reflects Financial Risks
(The following statement was released by the rating agency)
LONDON, September 15 (Fitch) Bayer's plan to partially finance
the acquisition
of Monsanto with a USD19bn equity and hybrid debt issuance
indicates it has
structured the deal to protect its balance sheet as much as
possible and manage
the financial risks, Fitch Ratings says. The deal is valued at
USD66bn, or
USD4bn more than when we placed Bayer on Rating Watch Negative
in May; however,
this increase is covered by the higher equity
Read more
LONDON, September 15 (Fitch) Bayer's plan to partially finance
the acquisition
of Monsanto with a USD19bn equity and hybrid debt issuance
indicates it has
structured the deal to protect its balance sheet as much as
possible and manage
the financial risks, Fitch Ratings says. The deal is valued at
USD66bn, or
USD4bn more than when we placed Bayer on Rating Watch Negative
in May; however,
this increase is covered by the higher equity
Read more
BRIEF-S&P downgrades Monsanto to 'BBB' on weak operations
* S&P - Monsanto Co. downgraded to 'BBB' on weak operations;
Ratings on creditwatch positive on planned acquisition by Bayer
AG
Read more
Ratings on creditwatch positive on planned acquisition by Bayer
AG
Read more
BRIEF-Blirt sees negative results in pre-clinical study of its BS-154
* Says pre-clinical study of its BS-154 shows no competitive
advantage and limited commercial implementation possibility for
cancer treatment
Read more
advantage and limited commercial implementation possibility for
cancer treatment
Read more
Farmers must have choice post Bayer-Monsanto merger - EU's Vestager
PARIS, Sept 15 (Reuters) - European Union anti-trust chief
Margrethe Vestager said on Thursday that farmers must continue
to have a choice when buying seeds and pesticides after the
merger between Bayer and Monsanto.
Read more
Margrethe Vestager said on Thursday that farmers must continue
to have a choice when buying seeds and pesticides after the
merger between Bayer and Monsanto.
Read more
RPT-Farmers must have choice post Bayer-Monsanto merger - EU's Vestager
PARIS, Sept 15 (Reuters) - European Union anti-trust chief
Margrethe Vestager said on Thursday that farmers must continue
to have a choice when buying seeds and pesticides after the
merger between Bayer and Monsanto.
Read more
Margrethe Vestager said on Thursday that farmers must continue
to have a choice when buying seeds and pesticides after the
merger between Bayer and Monsanto.
Read more
Teva Pharm, Intel to study Huntington disease progression
JERUSALEM, Sept 15 (Reuters) - Teva Pharmaceutical
Industries is collaborating with Intel Corp
to develop a wearable device and machine learning platform for
Huntington disease patients, Teva said on Thursday.
Read more
Industries is collaborating with Intel Corp
to develop a wearable device and machine learning platform for
Huntington disease patients, Teva said on Thursday.
Read more
BRIEF-Mimedx urges FDA to reconsider draft guidances
* Mimedx says continues to believe that its marketing of
its products as section 361 hct/ps is consistent with applicable
statutes and regulations
Read more
its products as section 361 hct/ps is consistent with applicable
statutes and regulations
Read more
UPDATE-1-AcelRx's opioid painkiller succeeds in key study
Sept 15 (Reuters) - AcelRx Pharmaceuticals Inc said
its experimental opioid painkiller was well tolerated in
post-operative patients, including those with organ impairment
and the elderly, in a late-stage study.
Read more
its experimental opioid painkiller was well tolerated in
post-operative patients, including those with organ impairment
and the elderly, in a late-stage study.
Read more
BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial
* Reports positive results for ARX-04 (sufentanil sublingual
tablet, 30 mcg), including in elderly patients and patients with
organ impairment, in third Phase 3 registration trial, SAP303
Read more
tablet, 30 mcg), including in elderly patients and patients with
organ impairment, in third Phase 3 registration trial, SAP303
Read more
BRIEF-Episurf Medical obtains its first granted patent in Australia
* Patent covers a surgical drilling guide with a functionality for depth adjustments
Source text for Eikon:
Read more
Source text for Eikon:
Read more
BRIEF-AnGes MG announces exercise of 22,500 options
* Says 22,500 of 28th warrants were exercised into 2.25
million shares of its common stock from Sep. 14 to Sep. 15,
including 250,000 shares at exercise price 222 yen and 2 million
shares at 214 yen
Read more
million shares of its common stock from Sep. 14 to Sep. 15,
including 250,000 shares at exercise price 222 yen and 2 million
shares at 214 yen
Read more
BRIEF-Novozymes acquires German research firm Organobalance
* Says will acquire Germany-based research company
Organobalance GmbH for an undisclosed price
Read more
Organobalance GmbH for an undisclosed price
Read more
BRIEF-KYORIN Holdings unit enters into co-promotion agreement with MSD K.K
* Says its unit Kyorin Pharmaceutical Company Limited enters
into agreement with MSD K.K, on co-promotion of an allergic
rhinitis treatment, since Nov. 1
Read more
into agreement with MSD K.K, on co-promotion of an allergic
rhinitis treatment, since Nov. 1
Read more
BRIEF-Pharnext confirms support for Hereditary Neuropathy Foundation
* Pharnext confirms its continuous support of the Hereditary Neuropathy Foundation to
increase global awareness of Charcot-Marie-Tooth (CMT) disease
Read more
increase global awareness of Charcot-Marie-Tooth (CMT) disease
Read more
Wednesday, September 14, 2016
Swiss stocks - Factors to watch on Sept 15
ZURICH, Sept 15 (Reuters) - The Swiss blue-chip SMI
was seen opening 0.2 percent lower at 8143 points on Thursday,
according to premarket indications by bank Julius Baer
.
Read more
was seen opening 0.2 percent lower at 8143 points on Thursday,
according to premarket indications by bank Julius Baer
.
Read more
UPDATE 1-Missouri lawmakers override gun, voter ID vetoes
KANSAS CITY, Mo. (Reuters) - Missouri lawmakers pushed
through bills on Wednesday eliminating the need for permits to
carry concealed weapons and requiring voters to show a photo
identification before casting a ballot, overriding Democratic
Governor Jay Nixon's vetoes of the bills.
Read more
through bills on Wednesday eliminating the need for permits to
carry concealed weapons and requiring voters to show a photo
identification before casting a ballot, overriding Democratic
Governor Jay Nixon's vetoes of the bills.
Read more
BRIEF-European Commission grants marketing authorisation for Kisplyx in combination with everolimus
* European commission grants marketing authorisation for
kisplyx (lenvatinib) in combination with everolimus in
advanced renal cell carcinoma
Read more
kisplyx (lenvatinib) in combination with everolimus in
advanced renal cell carcinoma
Read more
PRESS DIGEST- British Business - Sept 15
The following are the top stories on the business pages of
British newspapers. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
British newspapers. Reuters has not verified these stories and
does not vouch for their accuracy.
Read more
BRIEF-Centene expands marketplace offering in Arizona
* Says it estimates that its 2017 Ambetter offerings in
Arizona will provide incremental revenue of over $500 million
Read more
Arizona will provide incremental revenue of over $500 million
Read more
Missouri lawmakers override governor's veto of voter ID bill
KANSAS CITY, Mo., Sept 14 (Reuters) - Missouri lawmakers on
Wednesday overrode Governor Jay Nixon's veto of a bill requiring
voters to show government-issued photo identification in order
to cast a ballot in the state starting in 2017, after this
year's presidential election.
Read more
Wednesday overrode Governor Jay Nixon's veto of a bill requiring
voters to show government-issued photo identification in order
to cast a ballot in the state starting in 2017, after this
year's presidential election.
Read more
UPDATE 1-FDA panel recommends dropping serious warning on Pfizer's Chantix
Sept 14 (Reuters) - A serious warning on Pfizer Inc's
quit smoking drug should be removed, 10 of 19
independent panelists to the U.S. Food and Drug Administration
recommended on Wednesday, after reviewing additional trial data
on the controversial treatment.
Read more
quit smoking drug should be removed, 10 of 19
independent panelists to the U.S. Food and Drug Administration
recommended on Wednesday, after reviewing additional trial data
on the controversial treatment.
Read more
BRIEF-Ventas reports pricing of senior notes offering
* Priced a public offering of $450 million aggregate
principal amount of 3.25% senior notes due 2026 at 99.811% of
principal amount
Read more
principal amount of 3.25% senior notes due 2026 at 99.811% of
principal amount
Read more
BRIEF-Thermo Fisher prices offering of senior notes
* Priced offering of $1.2 billion aggregate principal amount
of its 2.950% senior notes due 2026 at issue price of 98.787% of
principal amount
Read more
of its 2.950% senior notes due 2026 at issue price of 98.787% of
principal amount
Read more
BRIEF-John Patience reports 5.1 pct passive stake in Neos Therapeutics
* John Patience reports 5.1 percent passive stake in Neos
Therapeutics Inc as of September 12 - Sec filing
Source text : http://bit.ly/2cOcAhq
Further company coverage:
Read more
Therapeutics Inc as of September 12 - Sec filing
Source text : http://bit.ly/2cOcAhq
Further company coverage:
Read more
FAA proposes $892,500 civil penalty against Air Methods Corp
WASHINGTON, Sept 14 (Reuters) - The U.S. Federal Aviation
Administration has proposed slapping a $892,500 civil penalty on
Air Methods Corp for allegedly operating a helicopter
on passenger-carrying flights when it was not airworthy, the
Transportation Department said on Wednesday.
Read more
Administration has proposed slapping a $892,500 civil penalty on
Air Methods Corp for allegedly operating a helicopter
on passenger-carrying flights when it was not airworthy, the
Transportation Department said on Wednesday.
Read more
BRIEF-GE Digital acquires Meridium Inc
* GE Digital acquires Meridium Inc to accelerate delivery of
comprehensive asset performance management offering for
customers
Read more
comprehensive asset performance management offering for
customers
Read more
CORRECTED-UPDATE 1-Clinton Foundation plans to spin off flagship health project
NEW YORK, Sept 14 (Reuters) - The Bill, Hillary & Chelsea
Clinton Foundation would spin off its flagship health project
into a "completely independent" charity if Hillary Clinton wins
the U.S. presidency in November, the charity announced on
Wednesday.
Read more
Clinton Foundation would spin off its flagship health project
into a "completely independent" charity if Hillary Clinton wins
the U.S. presidency in November, the charity announced on
Wednesday.
Read more
Korian raises 2016 core profit margin forecast
Sept 14 (Reuters) - French nursing home operator Korian
raised its core profit margin forecast for 2016 on
Wednesday due to one-off items in the first half and the impact
of IAS 17 accounting standards on its German acquisitions.
Read more
raised its core profit margin forecast for 2016 on
Wednesday due to one-off items in the first half and the impact
of IAS 17 accounting standards on its German acquisitions.
Read more
BRIEF-Le Noble Age H1 operating income rises to 17.5 million euros
* H1 net income group share 7.6 million euros ($8.56
million)versus 5.5 million euros year ago
Read more
million)versus 5.5 million euros year ago
Read more
UPDATE 2-Aspen Pharmacare moves into China as South Africa sales dip
JOHANNESBURG, Sept 14 (Reuters) - South Africa's Aspen
Pharmacare Holdings will use its recent acquisitions of
GlaxoSmithKline and AstraZeneca product lines to move into
China, the firm's chief executive said.
Read more
Pharmacare Holdings will use its recent acquisitions of
GlaxoSmithKline and AstraZeneca product lines to move into
China, the firm's chief executive said.
Read more
Fitch Rates Thermo Fisher's USD Senior Notes Offering 'BBB'; Outlook Stable
(The following statement was released by the rating agency)
NEW YORK, September 14 (Fitch) Fitch Ratings has assigned a
'BBB' rating to
Thermo Fisher Scientific Inc.'s (Thermo Fisher) new USD senior
notes offering.
Fitch expects that the proceeds of the issue will be used to
fund the early call
of the company's $900 million bond due February 2017 and for
general corporate
purposes. The Rating Outlook is Stable.
The ratings apply to approximately $15 billion of debt at June
30, 2016. A full
Read more
NEW YORK, September 14 (Fitch) Fitch Ratings has assigned a
'BBB' rating to
Thermo Fisher Scientific Inc.'s (Thermo Fisher) new USD senior
notes offering.
Fitch expects that the proceeds of the issue will be used to
fund the early call
of the company's $900 million bond due February 2017 and for
general corporate
purposes. The Rating Outlook is Stable.
The ratings apply to approximately $15 billion of debt at June
30, 2016. A full
Read more
BRIEF-IMS Health announces pricing on upsized offering of senior notes in connection with Quintiles IMS merger
* IMS Health announces pricing on upsized offering of senior
notes in connection with Quintiles IMS merger
Read more
notes in connection with Quintiles IMS merger
Read more
BRIEF-Pharmstandard majority shareholder increases its stake to 98.1 pct
* Says Augment Investments Limited under mandatory tender
offer acquired 4.5 million company ordinary shares from
remaining shareholders
Read more
offer acquired 4.5 million company ordinary shares from
remaining shareholders
Read more
South Africa's Tutu discharged from hospital after surgery
CAPE TOWN, Sept 14 (Reuters) - South African cleric and
anti-apartheid icon Desmond Tutu was discharged from hospital on
Wednesday after a successful surgery to treat recurring
infections that have afflicted him for more than a year, his
family said on Wednesday.
Read more
anti-apartheid icon Desmond Tutu was discharged from hospital on
Wednesday after a successful surgery to treat recurring
infections that have afflicted him for more than a year, his
family said on Wednesday.
Read more
BRIEF-Bayer targeting annual cost synergies of $1.2 bln -slides
* Says pays last 12 month ebitda multiple of 18.6x as of may
31, 2016; consensus(3) fy 2017 ebitda multiple of 16.5x
Read more
31, 2016; consensus(3) fy 2017 ebitda multiple of 16.5x
Read more
BRIEF-Biogen Inc affirms strong efficacy of TECFIDERA in both clinical studies and real-world setting
* New Data Affirm Strong Efficacy And well characterized
safety profile of TECFIDERA in both clinical studies and
real-world setting
Read more
safety profile of TECFIDERA in both clinical studies and
real-world setting
Read more
Deals of the day-Mergers and acquisitions
Sept 14 (Reuters) - The following bids, mergers,
acquisitions and disposals were reported by 1000 GMT on
Wednesday:
Read more
acquisitions and disposals were reported by 1000 GMT on
Wednesday:
Read more
UPDATE 1-Bayer signs deal worth close to $66 bln to buy Monsanto - source
* Bayer shares up 3 pct
(Adds calculation of overall deal size, comparison to past
deals, future market share)
Read more
(Adds calculation of overall deal size, comparison to past
deals, future market share)
Read more
Asterias stem cell therapy shows promise in spinal cord paralysis -U.S. study
NEW YORK, Sept 14 (Reuters) - An experimental stem cell
therapy developed by Asterias Biotherapeutics restored
some movement to patients paralyzed by recent spinal cord
injuries, according to interim data from a small study being
presented on Wednesday.
Read more
therapy developed by Asterias Biotherapeutics restored
some movement to patients paralyzed by recent spinal cord
injuries, according to interim data from a small study being
presented on Wednesday.
Read more
UPDATE 1-Swiss Alzheimer's biotech AC Immune eyes $700 mln IPO valuation
Sept 14 (Reuters) - AC Immune, the Swiss biotech company
working on treatments for Alzheimer's disease, has set the
pricing band for its keenly awaited U.S. initial public
offering, valuing the firm at about $700 million, at the top end
of the range.
Read more
working on treatments for Alzheimer's disease, has set the
pricing band for its keenly awaited U.S. initial public
offering, valuing the firm at about $700 million, at the top end
of the range.
Read more
BRIEF-Biogaia says probiotics to be launched in Kenya, Nigeria and Ghana
* Has signed an exclusive distributor agreement with
Phillips Pharma Group for the rights to sell Biogaia Protectis
drops, tablets and Oral Rehydration Solution in Kenya, Nigeria
and Ghana.
Read more
Phillips Pharma Group for the rights to sell Biogaia Protectis
drops, tablets and Oral Rehydration Solution in Kenya, Nigeria
and Ghana.
Read more
TABLE-Healthcare & Medical Investment -6 MTH results
Sep 14 (Reuters)
Healthcare & Medical Investment Corporation
FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months 6 months 6 months 6 months
ended Jul 31, 2016 ended Jan 31, 2016 to Jan 31, 2017 to Jul 31, 2017
LATEST PRIOR COMPANY COMPANY
RESULTS RESULTS FORECAST FORECA
Read more
Healthcare & Medical Investment Corporation
FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months 6 months 6 months 6 months
ended Jul 31, 2016 ended Jan 31, 2016 to Jan 31, 2017 to Jul 31, 2017
LATEST PRIOR COMPANY COMPANY
RESULTS RESULTS FORECAST FORECA
Read more
Tuesday, September 13, 2016
BRIEF-Alliance Pharma says H1 pretax profit up 113 pct
* Weakening of sterling against euro and us dollar that
developed during half year had effect of increasing sales by 2
pct
Read more
developed during half year had effect of increasing sales by 2
pct
Read more
BRIEF-Nanobiotix SA files for market approval in Europe for its product NBTXR3
* Has filed for market approval (CE marking) in Europe for
its product NBTXR3
Source text for Eikon:
Further company coverage:
Read more
its product NBTXR3
Source text for Eikon:
Further company coverage:
Read more
PRESS DIGEST- Financial Times - Sept 14
Sept 13 (Reuters) - The following are the top stories in the
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
Read more
Swiss biotech AC Immune sets IPO pricing range
Sept 13 (Reuters) - AC Immune SA on Tuesday set the pricing
range for its keenly awaited U.S. initial public offering,
valuing the Swiss biotech firm at about $700 million at the top
end of the range.
Read more
range for its keenly awaited U.S. initial public offering,
valuing the Swiss biotech firm at about $700 million at the top
end of the range.
Read more
BRIEF-Venaxis reports acquisition of Bioptix
* Acquired as of Sept 12, approximately 98% of voting
shares of Bioptix for about 14% of Venaxis post-deal outstanding
common shares
Source text for Eikon:
Further company coverage:
Read more
shares of Bioptix for about 14% of Venaxis post-deal outstanding
common shares
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Zynerba reports inducement grant to new chief financial officer
* Zynerba Pharmaceuticals reports inducement grant to new
chief financial officer
Source text for Eikon:
Further company coverage:
Read more
chief financial officer
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Hybrigenics recruits first patient in the clinical study of Inecalcitol
* Recruits the first patient in the clinical study of
Inecalcitol in acute myeloid leukemia
Source text for Eikon: http://bit.ly/2cpnU4p
Further company coverage:
(Gdynia Newsroom:)
Read more
Inecalcitol in acute myeloid leukemia
Source text for Eikon: http://bit.ly/2cpnU4p
Further company coverage:
(Gdynia Newsroom:)
Read more
UnitedHealth unit signs deal to take over most Quest billing
NEW YORK, Sept 13 (Reuters) - UnitedHealth Group Inc.
will fold most of Quest Diagnostics Inc's
customer billing into its Optum unit, including taking on 2,400
of the lab company's employees, increasing Optum's business for
such services by 20 percent.
Read more
will fold most of Quest Diagnostics Inc's
customer billing into its Optum unit, including taking on 2,400
of the lab company's employees, increasing Optum's business for
such services by 20 percent.
Read more
BRIEF-Aevis Victoria's subsidiary Swiss Medical Network to acquire Generale Beaulieu Holding SA
* Swiss medical network sa - acquisition offer to all the
shareholders of Generale Beaulieu Holding SA - Clinique
Générale-Beaulieu joining Swiss Medical Network
Read more
shareholders of Generale Beaulieu Holding SA - Clinique
Générale-Beaulieu joining Swiss Medical Network
Read more
BRIEF-Abivax completes the second milestone in Carena
* Abivax completes the second milestone in Carena, a
"strategic industrial innovation project" supported by Bpifrance
Source text for Eikon:
Further company coverage:
Read more
"strategic industrial innovation project" supported by Bpifrance
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Medtronic receives FDA approval of first drug-coated balloon for treatment of in-stent restenosis
* Medtronic Plc says receives FDA approval of first drug
coated balloon for treatment of in-stent restenosis
Read more
coated balloon for treatment of in-stent restenosis
Read more
BRIEF-Vista Partners updates coverage on Cachet Financial Solutions
* Vista Partners updates coverage on Cachet Financial
Solutions, Inc. (OTCQB: CAFN); price target to $21.50
Source text for Eikon:
Further company coverage:
Read more
Solutions, Inc. (OTCQB: CAFN); price target to $21.50
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Barry Honig submitted letter to CEO of Venaxis conveying concerns regarding co's failed strategic acquisition attempts
* On Sept 13, submitted letter to CEO of Venaxis conveying
concerns regarding co's failed strategic acquisition attempts -
SEC filing
Read more
concerns regarding co's failed strategic acquisition attempts -
SEC filing
Read more
National Grid Gas takes sterling market by storm in run-up to CBPS
LONDON, Sept 13 (IFR) - National Grid Gas Finance is poised
to sell the biggest ever corporate sterling bond on Tuesday, a
trade that could not have been better timed with the Bank of
England announcing the previous day that four of the issuer's
bonds were eligible for its purchase programme.
Read more
to sell the biggest ever corporate sterling bond on Tuesday, a
trade that could not have been better timed with the Bank of
England announcing the previous day that four of the issuer's
bonds were eligible for its purchase programme.
Read more
UPDATE 2-Alstom and French government clash over future of Belfort plant
PARIS, Sept 13 (Reuters) - Alstom will go ahead with plans
to shut down manufacturing at its Belfort plant in eastern
France, its CEO told staff on Tuesday, setting up a
confrontation with the French government which vowed "everything
will be done" to prevent that.
Read more
to shut down manufacturing at its Belfort plant in eastern
France, its CEO told staff on Tuesday, setting up a
confrontation with the French government which vowed "everything
will be done" to prevent that.
Read more
BRIEF-WellDoc announces agreement with LifeScan
* WellDoc announces agreement with LifeScan Inc, a Johnson &
Johnson diabetes care company, to finalize commercial
partnership to deliver combined, best-in-class digital
therapeutic solution for patients with type 2 diabetes
Source text for Eikon:
Further company coverage:
Read more
Johnson diabetes care company, to finalize commercial
partnership to deliver combined, best-in-class digital
therapeutic solution for patients with type 2 diabetes
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Aptinyx receives FDA fast track designation for development of NYX-2925
* Aptinyx receives FDA fast track designation for
development of NYX-2925 as treatment for neuropathic pain
associated with diabetic peripheral neuropathy
Source text for Eikon:
Further company coverage: [Aptinyx inc]
Read more
development of NYX-2925 as treatment for neuropathic pain
associated with diabetic peripheral neuropathy
Source text for Eikon:
Further company coverage: [Aptinyx inc]
Read more
BRIEF-Regenxbio publishes data from ongoing preclinical studies of NAV gene therapy in Neurodegenerative diseases
* Regenxbio publishes data from ongoing preclinical studies
of NAV gene therapy in neurodegenerative diseases
Read more
of NAV gene therapy in neurodegenerative diseases
Read more
BRIEF-Sichuan Languang Development's unit to acquire stake in Tianjin property firm
* Says unit plans to acquire stakes in property firm in
Tianjin city for 1.625 billion yuan ($243.29 million)
Read more
Tianjin city for 1.625 billion yuan ($243.29 million)
Read more
BRIEF-Insulet enrolls first patients in clinical trial for its Omnipod artificial pancreas system
* Enrolls first patients in clinical trial for its Omnipod
artificial pancreas system
Source text for Eikon:
Further company coverage:
Read more
artificial pancreas system
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Jianmin Pharmaceutical Group names chairman, president and CFO
* Says it names Liu Qinqiang as chairman of the board, Xu
Sheng as president and Wang Shaoquan as CFO
Read more
Sheng as president and Wang Shaoquan as CFO
Read more
WHO says Angola, Congo yellow fever outbreak under control
GENEVA, Sept 13 (Reuters) - A yellow fever outbreak in
Angola and Congo has been brought under control by a major
vaccination campaign, the head of pandemic and epidemic diseases
at the World Health Organization said on Tuesday.
Read more
Angola and Congo has been brought under control by a major
vaccination campaign, the head of pandemic and epidemic diseases
at the World Health Organization said on Tuesday.
Read more
Fosun Pharma looks to digest India's Gland, eyes other markets
SHANGHAI, Sept 13 (Reuters) - Chinese drugmaker Shanghai
Fosun Pharmaceutical Group Co Ltd already has one
eye on investments in other overseas markets after it announced
a nearly $1.3 billion deal in July to India's Gland Pharma, the
firm's chairman said on Tuesday.
Read more
Fosun Pharmaceutical Group Co Ltd already has one
eye on investments in other overseas markets after it announced
a nearly $1.3 billion deal in July to India's Gland Pharma, the
firm's chairman said on Tuesday.
Read more
BRIEF-Jiangsu Kanion Pharmaceutical to set up pharma JV
* Says it plans to set up pharma JV with registered capital
at 200 million yuan ($29.94 million)
Read more
at 200 million yuan ($29.94 million)
Read more
UPDATE 1-U.S. hedge fund Elliot Management ups Arcam stake, share rises
* U.S. hedge fund Elliot Management has raised its stake in
Swedish 3D printer maker Arcam to 6.6 percent of
shares and votes, through its investment vehicle Elliot Capital
Advisors, L.P., a filing from the Swedish FSA showed on Tuesday
Read more
Swedish 3D printer maker Arcam to 6.6 percent of
shares and votes, through its investment vehicle Elliot Capital
Advisors, L.P., a filing from the Swedish FSA showed on Tuesday
Read more
BRIEF-Mauna Kea Technologies Cellvizio placed at hospital in New York
* Announced on Monday the placement of a Cellvizio System,
the multidisciplinary confocal laser endomicroscopy platform,
at The Mount Sinai Hospital in New York, NY
Read more
the multidisciplinary confocal laser endomicroscopy platform,
at The Mount Sinai Hospital in New York, NY
Read more
Monday, September 12, 2016
Swiss stocks - Factors to watch on Sept 13
ZURICH, Sept 13 (Reuters) - The Swiss blue-chip SMI
was seen opening 0.5 percent higher at 8,243 points on Tuesday,
according to premarket indications by bank Julius Baer
.
Read more
was seen opening 0.5 percent higher at 8,243 points on Tuesday,
according to premarket indications by bank Julius Baer
.
Read more
BRIEF-Anges MG announces exercise of options
* Says 8,700 of 28th warrants were exercised into 870,000
shares of its common shares from Sep. 7 to Sep. 13, comprised of
170,000 shares at exercise price 233 yen, 270,000 shares at 230
yen, 100,000 shares at 234 yen, 180,000 shares at 229 yen and
150,000 at 219 yen
Read more
shares of its common shares from Sep. 7 to Sep. 13, comprised of
170,000 shares at exercise price 233 yen, 270,000 shares at 230
yen, 100,000 shares at 234 yen, 180,000 shares at 229 yen and
150,000 at 219 yen
Read more
BRIEF-Basilea: supply, distribution and license agreement with GBT
* Basilea announces supply, distribution and license agreement with Grupo Biotoscana for
CRESEMBA (isavuconazole) and Zevtera (ceftobiprole) in Latin America
Read more
CRESEMBA (isavuconazole) and Zevtera (ceftobiprole) in Latin America
Read more
Cancer overtakes heart disease as Australia's biggest killer
SYDNEY, Sept 13 (Reuters) - Cancer has become Australia's
biggest killer, overtaking heart disease for the first time to
take more lives than any other ailment, a government health
agency said in a report released on Tuesday.
Read more
biggest killer, overtaking heart disease for the first time to
take more lives than any other ailment, a government health
agency said in a report released on Tuesday.
Read more
UPDATE 2-Obama asks U.S. insurers for help enrolling the young and healthy
Sept 12 (Reuters) - President Barack Obama on Monday urged
U.S. insurers offering coverage next year under his national
healthcare law to step up their efforts to enroll those who
remain uninsured, especially younger and healthier Americans.
Read more
U.S. insurers offering coverage next year under his national
healthcare law to step up their efforts to enroll those who
remain uninsured, especially younger and healthier Americans.
Read more
UPDATE 1-Obama hopeful on spending, Zika funds after meeting Congress leaders
WASHINGTON, Sept 12 (Reuters) - President Barack Obama said
after meeting with the top four congressional leaders on Monday
he was encouraged that lawmakers would be able to pass short
term spending legislation to keep the government open during the
2017 fiscal year.
Read more
after meeting with the top four congressional leaders on Monday
he was encouraged that lawmakers would be able to pass short
term spending legislation to keep the government open during the
2017 fiscal year.
Read more
Obama asks U.S. insurers for help enrolling the young and healthy
Sept 12 (Reuters) - President Barack Obama on Monday urged
U.S. insurers offering coverage next year under his national
healthcare law to step up their efforts to enroll those who
remain uninsured, especially younger and healthier Americans.
Read more
U.S. insurers offering coverage next year under his national
healthcare law to step up their efforts to enroll those who
remain uninsured, especially younger and healthier Americans.
Read more
BRIEF-Catherine Johanna Defrancesco reports 7.49 pct stake in Venaxis as of Sept. 2
* Catherine Johanna Defrancesco reports 7.49 percent stake
in Venaxis Inc as of Sept. 2 - Sec filing
Source text (http://bit.ly/2czSv2y)
Further company coverage:
Read more
in Venaxis Inc as of Sept. 2 - Sec filing
Source text (http://bit.ly/2czSv2y)
Further company coverage:
Read more
Obama says hopeful on spending, Zika after meeting Congress leaders
WASHINGTON, Sept 12 (Reuters) - President Barack Obama said
after meeting with congressional leaders on Monday he was
encouraged that Congress would be able to pass short term
spending legislation to keep the government open.
Read more
after meeting with congressional leaders on Monday he was
encouraged that Congress would be able to pass short term
spending legislation to keep the government open.
Read more
Engine failure led to foot-long hole in Southwest airliner -agency
Sept 12 (Reuters) - An engine failure on a Southwest
Airlines Co jet on Aug. 27 released debris that tore a 5
inch by 16 inch (13 cm by 41 cm) hole in the plane before it
made a safe emergency landing in Pensacola, Florida, U.S. crash
investigators said on Monday.
Read more
Airlines Co jet on Aug. 27 released debris that tore a 5
inch by 16 inch (13 cm by 41 cm) hole in the plane before it
made a safe emergency landing in Pensacola, Florida, U.S. crash
investigators said on Monday.
Read more
BRIEF-Bow Street LLC reports 5.3 pct passive stake in Adamas Pharmaceuticals as of Sept 2
* Bow Street Llc reports 5.3 percent passive stake in Adamas
Pharmaceuticals Inc as of September 2 -Sec filing
Source text (http://bit.ly/2cI06YG)
Further company coverage:
Read more
Pharmaceuticals Inc as of September 2 -Sec filing
Source text (http://bit.ly/2cI06YG)
Further company coverage:
Read more
RPT-UPDATE 3-FDA staff flags concerns about Pfizer's quit-smoking drug study
Sept 12 (Reuters) - Pfizer Inc's trial data on
Chantix, a drug to help people quit smoking, failed to impress
U.S. Food and Drug Administration scientists, in a blow to the
company's attempts to have a serious warning removed from the
drug's label.
Read more
Chantix, a drug to help people quit smoking, failed to impress
U.S. Food and Drug Administration scientists, in a blow to the
company's attempts to have a serious warning removed from the
drug's label.
Read more
UPDATE 1-UK will have public guidelines for Brexit talks before triggering Article 50 - minister
LONDON, Sept 12 (Reuters) - Britain will make public its
guidelines for talks on leaving the European Union by the time
it triggers the exit process, Brexit minister David Davis said
on Monday, in the first indication of when Britons will find out
what the government hopes to achieve in the talks.
Read more
guidelines for talks on leaving the European Union by the time
it triggers the exit process, Brexit minister David Davis said
on Monday, in the first indication of when Britons will find out
what the government hopes to achieve in the talks.
Read more
UPDATE 2-FDA staff flags concerns about Pfizer's quit-smoking drug study
Sept 12 (Reuters) - Pfizer Inc's trial data on
Chantix, a drug to help people quit smoking, failed to impress
U.S. Food and Drug Administration scientists, in a blow to the
company's attempts to have a serious warning removed from the
drug's label.
Read more
Chantix, a drug to help people quit smoking, failed to impress
U.S. Food and Drug Administration scientists, in a blow to the
company's attempts to have a serious warning removed from the
drug's label.
Read more
RPT-UPDATE 2-Horizon Pharma to buy Raptor Pharma for $800 mln
Sept 12 (Reuters) - Horizon Pharma Plc said it
would buy Raptor Pharmaceutical Corp for nearly $800
million to bolster its portfolio of drugs to treat rare diseases
and reduce its dependence on the primary care market.
Read more
would buy Raptor Pharmaceutical Corp for nearly $800
million to bolster its portfolio of drugs to treat rare diseases
and reduce its dependence on the primary care market.
Read more
UPDATE 2-Horizon Pharma to buy Raptor Pharma for $800 mln
Sept 12 (Reuters) - Horizon Pharma Plc said it
would buy Raptor Pharmaceutical Corp for nearly $800
million to bolster its portfolio of drugs to treat rare diseases
and reduce its dependence on the primary care market.
Read more
would buy Raptor Pharmaceutical Corp for nearly $800
million to bolster its portfolio of drugs to treat rare diseases
and reduce its dependence on the primary care market.
Read more
UPDATE 2-Trump says health is an 'issue' after Clinton pneumonia revelation
WASHINGTON, Sept 12 (Reuters) - Republican presidential
candidate Donald Trump said on Monday that health is an issue in
the election campaign after his Democratic rival, Hillary
Clinton, revealed she had pneumonia, and he said he would soon
release detailed information about his health.
Read more
candidate Donald Trump said on Monday that health is an issue in
the election campaign after his Democratic rival, Hillary
Clinton, revealed she had pneumonia, and he said he would soon
release detailed information about his health.
Read more
BRIEF-Regeneron says Bonnie Bassler, Huda Zoghbi elected to board
* Regeneron announces election of Bonnie Bassler, ph.d., and
Huda Zoghbi, m.d., to board of directors
Source text for Eikon:
Further company coverage:
Read more
Huda Zoghbi, m.d., to board of directors
Source text for Eikon:
Further company coverage:
Read more
BRIEF-FDA staff say neuropsychiatric risk with Pfizer's quit-smoking drug varies in studies, trial design has limitations
* Neuropsychiatric risk with Pfizer's quit-smoking drug
varies in studies, trial design has limitations & biases that
affect interpretation
Read more
varies in studies, trial design has limitations & biases that
affect interpretation
Read more
BRIEF-Xencor doses first patient in blood cancer test
* Oncology bispecific program XmAb14045 for the treatment of
acute myeloid leukemia and other CD123-expressing hematologic
malignancies
Read more
acute myeloid leukemia and other CD123-expressing hematologic
malignancies
Read more
BRIEF-Karyopharm appoints Humphrey A.R.Gardner as senior VP, clinical development
* Karyopharm appoints Humphrey A.R. Gardner MD, FCAP, as
senior vice president, clinical development
Source text for Eikon:
Further company coverage:
Read more
senior vice president, clinical development
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Horizon Pharma Plc to acquire Raptor Pharmaceutical corp
* Horizon Pharma Plc to acquire Raptor Pharmaceutical Corp.
as further step in building leading rare disease business
Read more
as further step in building leading rare disease business
Read more
BRIEF-Intercept said on Sept 8, court granted final approval of previously announced agreement with lead plaintiff
* On Sept 8, court granted final approval of previously
announced agreement with lead plaintiff to settle purported
securities class action litigation
Read more
announced agreement with lead plaintiff to settle purported
securities class action litigation
Read more
BRIEF-Nexstim concludes co-operation negotiations
* Maximum of 2 people will be permanently laid off and one person will be working part time
in future
Read more
in future
Read more
Investors stay positive as corporate yields turn negative
LONDON, Sept 12 (IFR) - Investors, doing their best to
remain positive even as corporate bonds descend deeper into
negative yielding territory, bought two new issues with negative
yields last week as the strength of central bank action
continued to promote perverse incentives.
Read more
remain positive even as corporate bonds descend deeper into
negative yielding territory, bought two new issues with negative
yields last week as the strength of central bank action
continued to promote perverse incentives.
Read more
GSK sells anaesthetics to Aspen for up to $370 mln
LONDON, Sept 12 (Reuters) - GlaxoSmithKline is to
sell its portfolio of anaesthetic drugs to South Africa's Aspen
Pharmacare for up to 280 million pounds ($372 million)
as part of a drive by the British drugmaker to focus on core
therapy areas.
Read more
sell its portfolio of anaesthetic drugs to South Africa's Aspen
Pharmacare for up to 280 million pounds ($372 million)
as part of a drive by the British drugmaker to focus on core
therapy areas.
Read more
BRIEF-Aspen Pharma to buy almost entire of GSK's anaesthetics portfolio
* Signed an agreement with GSK whereby AGI will acquire a
portfolio of anaesthetics globally with exception of certain
territories
Read more
portfolio of anaesthetics globally with exception of certain
territories
Read more
Thai authorities downplay Zika risk, worried by tourism impact
BANGKOK, Sept 12 (Reuters) - Health and city officials in
Thailand downplayed risks from rising infections from the
mosquito-borne Zika virus, which is linked to serious birth
defects, and expressed concern that disclosing information would
damage its tourism industry.
Read more
Thailand downplayed risks from rising infections from the
mosquito-borne Zika virus, which is linked to serious birth
defects, and expressed concern that disclosing information would
damage its tourism industry.
Read more
Sunday, September 11, 2016
BRIEF-Pixium Vision gets clinical trial approval from Spanish Ministry of Health
* Pixium Vision receives clinical trial approval from Spanish Ministry of Health for 150
electrode IRIS II bionic vision system
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
electrode IRIS II bionic vision system
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Swiss biotech firm ADIENNE says plans IPO
ZURICH, Sept 12 (Reuters) - Swiss biotechnology firm ADIENNE
said on Monday it plans to seek a listing on Switzerland's
bourse in an initial public offering.
Read more
said on Monday it plans to seek a listing on Switzerland's
bourse in an initial public offering.
Read more
BRIEF-Onxeo announces first outcomes of Livatag preclinical plan
* Livatag nanoformulation leads to increased exposure and preferential affinity for liver,
supporting current relive phase III study rationale
Read more
supporting current relive phase III study rationale
Read more
BRIEF-LG Chem to merge with LG Life Sciences Ltd
* Says merger rate of 1 : 0.2606772 for common shares and 1
: 0.2534945 for preferred shares between the company and LG Life
Sciences
Read more
: 0.2534945 for preferred shares between the company and LG Life
Sciences
Read more
UPDATE 1-LG Chem to buy LG Life Sciences for nearly $1 bln
SEOUL, Sept 12 (Reuters) - South Korean chemicals and
battery maker LG Chem on Monday said it plans to
acquire pharmaceutical affiliate LG Life Sciences
for about 1.1 trillion won ($989.56 million) to make its bio
business a new growth engine.
Read more
battery maker LG Chem on Monday said it plans to
acquire pharmaceutical affiliate LG Life Sciences
for about 1.1 trillion won ($989.56 million) to make its bio
business a new growth engine.
Read more
LG Chem says to buy LG Life Sciences to boost bio business
SEOUL, Sept 12 (Reuters) - South Korean chemicals and
battery maker LG Chem on Monday said it plans to
acquire pharmaceutical affiliate LG Life Sciences to
expand its bio business.
(Reporting by Hyunjoo Jin; Editing by Stephen Coates)
Read more
battery maker LG Chem on Monday said it plans to
acquire pharmaceutical affiliate LG Life Sciences to
expand its bio business.
(Reporting by Hyunjoo Jin; Editing by Stephen Coates)
Read more
BRIEF-BeiGene receives approval to initiate clinical trials in China with PD-1 antibody BGB-A317
* Beigene Receives Approval To Initiate Clinical Trials In
China With Pd-1 antibody bgb-a317
Read more
China With Pd-1 antibody bgb-a317
Read more
UPDATE 1-Merkel aide optimistic conservatives will overcome migrant cap dispute
BERLIN, Sept 11 (Reuters) - Chancellor Angela Merkel's Chief
of Staff said on Sunday he was confident Germany's sister
conservative parties, whose unity is threatened by a row over
migrant policy just a year before a federal election, would soon
sort out their differences.
Read more
of Staff said on Sunday he was confident Germany's sister
conservative parties, whose unity is threatened by a row over
migrant policy just a year before a federal election, would soon
sort out their differences.
Read more
U.S. Justice Department subpoenas Taro over generic drug pricing
WASHINGTON, Sept 11 (Reuters) - Taro Pharmaceutical
Industries Ltd. and two of its senior officers received
grand jury subpoenas last week in connection with a federal
antitrust investigation into generic drug pricing, the company
disclosed late on Friday.
Read more
Industries Ltd. and two of its senior officers received
grand jury subpoenas last week in connection with a federal
antitrust investigation into generic drug pricing, the company
disclosed late on Friday.
Read more
Eight pregnant women among 329 infected by Zika in Singapore-govt
SINGAPORE, Sept 11 (Reuters) - Eight pregnant women have
been infected by the Zika virus among the 329 cases in
Singapore, the government said on Sunday.
Read more
been infected by the Zika virus among the 329 cases in
Singapore, the government said on Sunday.
Read more
Israel Chemicals faces tough road to recovery after CEO steps down
JERUSALEM, Sept 11 (Reuters) - Stefan Borgas stepping down
as chief executive is the latest in a series of issues that have
plagued Israel Chemicals (ICL), and the company's
fortunes are not expected to turn around in the foreseeable
future given very low potash prices.
Read more
as chief executive is the latest in a series of issues that have
plagued Israel Chemicals (ICL), and the company's
fortunes are not expected to turn around in the foreseeable
future given very low potash prices.
Read more
Hollande to meet ministers over Alstom's plans for Belfort plant
PARIS, Sept 11 (Reuters) - French President Francois
Hollande will meet Prime Minister Manuel Valls and ministers in
charge of economic and transport policy on Monday morning to
discuss trainmaker Alstom's sudden decision to scale down its
Belfort plant, the president's office said.
Read more
Hollande will meet Prime Minister Manuel Valls and ministers in
charge of economic and transport policy on Monday morning to
discuss trainmaker Alstom's sudden decision to scale down its
Belfort plant, the president's office said.
Read more
Thailand finds 21 new cases of Zika in Bangkok, including pregnant woman
BANGKOK, Sept 11 (Reuters) - Twenty-one new cases of
locally-transmitted Zika virus have been confirmed in central
Bangkok, including a pregnant woman who later gave birth with no
complications, Thailand's public health ministry said on Sunday.
Read more
locally-transmitted Zika virus have been confirmed in central
Bangkok, including a pregnant woman who later gave birth with no
complications, Thailand's public health ministry said on Sunday.
Read more
Saturday, September 10, 2016
BRIEF-Cytokinetics announces additional results from COSMIC-HF
* Announces additional results from COSMIC-HF to be
presented at the HFSA Annual Scientific Meeting
Source text for Eikon:
Further company coverage:
Read more
presented at the HFSA Annual Scientific Meeting
Source text for Eikon:
Further company coverage:
Read more
Friday, September 9, 2016
BRIEF-Unitedhealth says Director Richard Burke reports open market sale of 20,000 shares of co
* Director Richard Burke reports open market sale of 20,000
shares of co's common stock at average price of $135.8 per share
on SEPT 7 - SEC filing
Source: (http://bit.ly/2c6wYif)
Further company coverage:
Read more
shares of co's common stock at average price of $135.8 per share
on SEPT 7 - SEC filing
Source: (http://bit.ly/2c6wYif)
Further company coverage:
Read more
Executives see little progress on easing Cuba-U.S. financial services
NEW YORK, Sept 9 (Reuters) - Multinational financial
companies met on Friday with U.S. and Cuban officials to discuss
making financial transactions between the two countries easier
but reported no concrete signs of progress.
Read more
companies met on Friday with U.S. and Cuban officials to discuss
making financial transactions between the two countries easier
but reported no concrete signs of progress.
Read more
BRIEF-Biodel enters into an asset purchase and license agreement with Unilife Corp and Unilife Medical Solutions
* On September 2, 2016, co, Unilife Corp and Unilife Medical
Solutions Inc entered into an asset purchase and license
agreement
Read more
Solutions Inc entered into an asset purchase and license
agreement
Read more
BRIEF-Promis Neurosciences announces completion of private placement offering
* Announces completion of private placement offering
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-GE sets quarterly dividend of $0.23 per share
* Sets quarterly dividend of $0.23 per share
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
UPDATE 2-Teva says aims to launch EpiPen-like device by 2018 in U.S.
Sept 9 (Reuters) - Teva Pharmaceutical Industries Ltd
said Friday it aims to win U.S. approval by late 2017
or early 2018 for its version of Mylan NV's EpiPen
device for treating severe allergic reactions, a move that would
challenge the branded product's overwhelming market dominance.
Read more
said Friday it aims to win U.S. approval by late 2017
or early 2018 for its version of Mylan NV's EpiPen
device for treating severe allergic reactions, a move that would
challenge the branded product's overwhelming market dominance.
Read more
BRIEF-Abbvie sets quarterly cash dividend of $0.57per share
* Sets quarterly cash dividend of $0.57per share
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Apobiologix comments on patent infringement litigation about Grastofil, Lapelga
* Positive Court Decision In Patent Infringement Litigation
Against Amgen Concerning Grastofil And Lapelga Products
Read more
Against Amgen Concerning Grastofil And Lapelga Products
Read more
Teva says hoping to launch EpiPen-like device by 2018 in U.S.
Sept 9 (Reuters) - Teva Pharmaceutical Industries Ltd
on Friday said it hopes to win U.S. approval by late
2017 or early 2018 for its version of Mylan NV's EpiPen
device to treat severe allergic reactions, a move that could
challenge the branded product's overwhelming dominance.
Read more
on Friday said it hopes to win U.S. approval by late
2017 or early 2018 for its version of Mylan NV's EpiPen
device to treat severe allergic reactions, a move that could
challenge the branded product's overwhelming dominance.
Read more
Clinton spokeswoman defends drug plan after Pfizer comments
NEW YORK, Sept 9 (Reuters) - U.S. Presidential candidate
Hillary Clinton's spokeswoman said on Friday Clinton's plan to
curb drug spending was not the blow to medical innovation that
Pfizer Inc Chief Executive Ian Read described it as
being on Thursday.
Read more
Hillary Clinton's spokeswoman said on Friday Clinton's plan to
curb drug spending was not the blow to medical innovation that
Pfizer Inc Chief Executive Ian Read described it as
being on Thursday.
Read more
BRIEF-Novo Nordisk issues nationwide recall of six batches of glucagen hypokit
* Novo Nordisk Inc issues voluntary nationwide recall of six
batches of glucagen hypokit due to detached needles on syringe
in kit
Read more
batches of glucagen hypokit due to detached needles on syringe
in kit
Read more
BRIEF-ViewRay wins China FDA approval for its MRIdian system
* Says has received china food and drug administration
approval for its mridian system
Source text for Eikon:
Further company coverage:
Read more
approval for its mridian system
Source text for Eikon:
Further company coverage:
Read more
EU regulators halt Dow, DuPont merger review to gather data
BRUSSELS, Sept 9 (REUTERS) - EU antitrust regulators have
halted their scrutiny of Dow Chemical Co and DuPont's
proposed merger while the companies provide more
information regarding their $130 billion deal.
Read more
halted their scrutiny of Dow Chemical Co and DuPont's
proposed merger while the companies provide more
information regarding their $130 billion deal.
Read more
BRIEF-Medivir reports positive phase IIa data for simeprevir
* Interim results from phase IIa trial evaluating triple
combination including simeprevir demonstrates high level of
efficacy in HCV patients
Read more
combination including simeprevir demonstrates high level of
efficacy in HCV patients
Read more
UPDATE 1-Ivory Coast re-opens western borders closed during Ebola epidemic
ABIDJAN, Sept 9 (Reuters) - Ivory Coast has re-opened its
western borders with Liberia and Guinea two years after they
were closed to prevent the spread of an Ebola epidemic that
killed thousands across West Africa, an Ivorian government
spokesman said on Friday.
Read more
western borders with Liberia and Guinea two years after they
were closed to prevent the spread of an Ebola epidemic that
killed thousands across West Africa, an Ivorian government
spokesman said on Friday.
Read more
Ivory Coast re-opens western borders closed during Ebola epidemic
ABIDJAN, Sept 9 (Reuters) - Ivory Coast has re-opened its
western borders with Liberia and Guinea two years after they
were closed to prevent the spread of an Ebola epidemic that
killed thousands across West Africa, an Ivorian government
spokesman said on Friday.
Read more
western borders with Liberia and Guinea two years after they
were closed to prevent the spread of an Ebola epidemic that
killed thousands across West Africa, an Ivorian government
spokesman said on Friday.
Read more
UPDATE 1-Duterte says he told Obama he never insulted him, thinks UN's Ban a fool
JAKARTA, Sept 9 (Reuters) - Philippine President Rodrigo
Duterte told Barack Obama he never called him a "son of a
bitch", he said on Friday, but he maintained a defiant stance on
his war on drugs, saying U.N. chief Ban Ki-moon was a fool for
bringing up human rights.
Read more
Duterte told Barack Obama he never called him a "son of a
bitch", he said on Friday, but he maintained a defiant stance on
his war on drugs, saying U.N. chief Ban Ki-moon was a fool for
bringing up human rights.
Read more
BRIEF-Cellumed to issue 3 bln won worth convertible bonds
* Says it will issue the 16th unregistered/unsecured private
convertible bonds, raising 3 billion won in proceeds for
operations
Read more
convertible bonds, raising 3 billion won in proceeds for
operations
Read more
BRIEF-Sage Therapeutics announces public offering of 4.40 mln common shares priced at $39.75/share
* Says public offering of 4.40 million common shares priced
at $39.75per share
Source text for Eikon:
Further company coverage:
Read more
at $39.75per share
Source text for Eikon:
Further company coverage:
Read more
Duterte says he told Obama he never insulted him, thinks UN's Ban a fool
JAKARTA, Sept 9 (Reuters) - Philippine President Rodrigo
Duterte told Barack Obama he never called him a "son of a
bitch", he said on Friday, but he maintained a defiant stance on
his war on drugs, saying U.N. chief Ban Ki-moon was a fool for
bringing up human rights.
Read more
Duterte told Barack Obama he never called him a "son of a
bitch", he said on Friday, but he maintained a defiant stance on
his war on drugs, saying U.N. chief Ban Ki-moon was a fool for
bringing up human rights.
Read more
BRIEF-Caregen to invest 32.8 bln won to establish new unit in US
* Says it will invest 32.8 billion won to establish new
wholly owned unit in the United States, namely Caregen Biopharma
Inc.
Read more
wholly owned unit in the United States, namely Caregen Biopharma
Inc.
Read more
Thursday, September 8, 2016
BRIEF-Pihlajalinna signs deal with Tervola municipality
* Says Tervola has chosen Pihlajalinna as municipality's social and healthcare services
partner
Read more
partner
Read more
BRIEF-Dechra Pharmaceuticals gets FDA approval for first U.S. generic entrant antibiotic
* Dechra is pleased to announce that it has received
approval from the U.S. Food and Drug Administration (FDA) for a
generic antibiotic
Read more
approval from the U.S. Food and Drug Administration (FDA) for a
generic antibiotic
Read more
German stocks - Factors to watch on September 9
FRANKFURT/BERLIN, Sept 9 (Reuters) - The following are some
of the factors that may move German stocks on Friday:
Read more
of the factors that may move German stocks on Friday:
Read more
BRIEF-Novartis says Niji system may provide earlier diagnosis of severe allergic asthma
* Says new Novartis point of care Niji system may provide
earlier diagnosis of severe allergic asthma and faster treatment
decisions
Source text for Eikon: [http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20160909:nGNERJK5S
]
Further company coverage:
(Reporting by Zurich Newsroom)
Read more
earlier diagnosis of severe allergic asthma and faster treatment
decisions
Source text for Eikon: [http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20160909:nGNERJK5S
]
Further company coverage:
(Reporting by Zurich Newsroom)
Read more
BRIEF-Celltrion receives patent
* Says it receives patent on Sept. 9, for human monoclonal
antibody generated from human B-cells able to neutralize
influenza A viruses
Read more
antibody generated from human B-cells able to neutralize
influenza A viruses
Read more
Mistrust of vaccines is greatest in France - survey
LONDON, Sept 9 (Reuters) - Public confidence in immunisation
varies widely across the world with the French the most
sceptical about the safety of vaccines, according to a survey
published on Friday.
Read more
varies widely across the world with the French the most
sceptical about the safety of vaccines, according to a survey
published on Friday.
Read more
Statins' benefits understated and harms exaggerated, scientists warn
LONDON, Sept 8 (Reuters) - The benefits of statins -
cholesterol-busting drugs that can dramatically reduce the risk
of heart attacks and strokes - have been underestimated and
their harms exaggerated, scientists said on Thursday in a major
review of research.
Read more
cholesterol-busting drugs that can dramatically reduce the risk
of heart attacks and strokes - have been underestimated and
their harms exaggerated, scientists said on Thursday in a major
review of research.
Read more
BRIEF-Broadwood Partners reports 13.8 pct stake in Oncocyte Corp
* Reports 13.8 percent stake in Oncocyte Corp, as of August
29, 2016 - SEC filing
Source: (http://bit.ly/2cdBnNj)
Further company coverage:
Read more
29, 2016 - SEC filing
Source: (http://bit.ly/2cdBnNj)
Further company coverage:
Read more
CORRECTED-BRIEF-iCAD says co's CFO and COO Kevin Burns to resign
* Kevin Burns, president, chief financial officer and chief
operating officer, is resigning from company effective September
23, 2016
Read more
operating officer, is resigning from company effective September
23, 2016
Read more
U.S. taxable bond funds net $3.4 bln in latest week - Lipper
NEW YORK, Sept 8 (Reuters) - Investors added $3.4 billion in
cash to U.S.-based taxable bond funds during the week through
Sept. 7, Thomson Reuters Lipper data showed on Thursday, marking
the funds' fourth week in five of posting positive flows.
Read more
cash to U.S.-based taxable bond funds during the week through
Sept. 7, Thomson Reuters Lipper data showed on Thursday, marking
the funds' fourth week in five of posting positive flows.
Read more
"Trojan Horse" antibody plan shows promise against Ebola viruses
LONDON, Sept 8 (Reuters) - Scientists have found a hidden
weak spot shared by all five known types of the deadly Ebola
virus and successfully targeted it with two antibodies which
blocked its ability to invade human cells.
Read more
weak spot shared by all five known types of the deadly Ebola
virus and successfully targeted it with two antibodies which
blocked its ability to invade human cells.
Read more
UPDATE 1-Biden asks U.S. Congress to allow unencumbered Zika funding vote
WASHINGTON, Sept 8 (Reuters) - Vice President Joe Biden on
Thursday called on the Republican-led U.S. Congress to allow an
up-or-down vote on funding to combat the Zika virus without
other provisions attached, calling the health threat posed by
the pathogen a national emergency.
Read more
Thursday called on the Republican-led U.S. Congress to allow an
up-or-down vote on funding to combat the Zika virus without
other provisions attached, calling the health threat posed by
the pathogen a national emergency.
Read more
BRIEF-Bayer to explore sale of $1.1 bln dermatology business - Bloomberg
* Bayer said to explore sale of $1.1 billion dermatology
business - Bloomberg, citing source
Read more
business - Bloomberg, citing source
Read more
BRIEF-Boiron H1 net income group share rises 23.3 pct
* Reports H1 net income group share of 26.5 million euros
versus 21.5 million euros a year ago
See also:
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
versus 21.5 million euros a year ago
See also:
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
German online pharmacy Shop-Apotheke plans Frankfurt listing - sources
FRANKFURT, Sept 8 (Reuters) - Online pharmacy Shop Apotheke
is planning a Frankfurt stock market listing as it seeks to
generate cash for its expansion, taking advantage of buoyant
equity markets, people familiar with the matter said.
Read more
is planning a Frankfurt stock market listing as it seeks to
generate cash for its expansion, taking advantage of buoyant
equity markets, people familiar with the matter said.
Read more
UPDATE 1-French govt summons Alstom boss over end to trainmaking in Belfort
PARIS, Sept 8 (Reuters) - The head of Alstom was
summoned by the French government for an explanation on Thursday
after the company revealed plans to bring over 130 years of
trainmaking to an end at its Belfort plant in eastern France.
Read more
summoned by the French government for an explanation on Thursday
after the company revealed plans to bring over 130 years of
trainmaking to an end at its Belfort plant in eastern France.
Read more
UPDATE 1-EU court says Lundbeck pay-for-delay deals anti-competitive
LUXEMBOURG, Sept 8 (Reuters) - Danish drugmaker Lundbeck's
deals with smaller rivals to delay cheaper generic
copies of its blockbuster citalopram anti-depressant from
entering the market were anti-competitive, a European Union
court said on Thursday.
Read more
deals with smaller rivals to delay cheaper generic
copies of its blockbuster citalopram anti-depressant from
entering the market were anti-competitive, a European Union
court said on Thursday.
Read more
BRIEF-Clovis Oncology -FDA has notified it is not currently planning to hold advisory committee meeting to discuss for Rucaparib
* FDA has notified co that FDA is not currently planning to
hold advisory committee meeting to discuss NDA for Rucaparib
Source text: [http://bit.ly/2c9EYtK]
Further company coverage:
Read more
hold advisory committee meeting to discuss NDA for Rucaparib
Source text: [http://bit.ly/2c9EYtK]
Further company coverage:
Read more
BRIEF-Chrono Therapeutics raises $47.6 million in series B financing
* Chrono Therapeutics raises $47.6 million in series B
financing to advance its clinical platform for personalized drug
therapy
Read more
financing to advance its clinical platform for personalized drug
therapy
Read more
BRIEF-PZ Cormay to issue series L shares to shareholders of Orphee
* To issue up to 16,695,541 series L shares to shareholders
of Orphee SA in exchange for Orphee's shares
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
of Orphee SA in exchange for Orphee's shares
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Octiv says secured a investment from GE Ventures
* Octiv says investment was part of a round totaling $4.75
million
Source text for Eikon:
Further company coverage:
Read more
million
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Health&Life says change of general manager
* Says its general manager resigned on Sep. 2 and it
appoints Paul Yang as acting general manager
Read more
appoints Paul Yang as acting general manager
Read more
Subscribe to:
Posts (Atom)